China Jo-Jo Drugstores 10-Q 14 Nov 17 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Sep. 30, 2017	Nov. 13, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	CHINA JO-JO DRUGSTORES, INC.
Entity Central Index Key	1,413,263
Trading Symbol	CJJD
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,018
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		25,214,678

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2017	Mar. 31, 2017
CURRENT ASSETS
Cash	$ 16,837,873	$ 18,364,424
Restricted cash	10,277,758	9,431,386
Financial assets available for sale	165,282	87,068
Notes receivable	312,570	253,394
Trade accounts receivable	10,200,542	8,561,596
Inventories	11,077,027	9,923,101
Other receivables, net	2,624,059	2,269,193
Advances to suppliers	3,914,099	5,504,141
Other current assets	1,804,654	1,566,155
Total current assets	57,213,864	55,960,458
PROPERTY AND EQUIPMENT, net	4,533,390	4,263,157
OTHER ASSETS
Long-term investment	46,501	46,152
Farmland assets	744,256	718,787
Long term deposits	3,202,793	2,294,848
Other noncurrent assets	1,327,447	1,177,005
Intangible assets, net	3,097,546	2,712,611
Total other assets	8,418,543	6,949,403
Total assets	70,165,797	67,173,018
CURRENT LIABILITIES
Accounts payable, trade	23,089,541	19,441,195
Notes payable	12,872,045	12,691,575
Other payables	2,735,247	2,916,283
Other payables - related parties	859,191	927,052
Customer deposits	3,083,129	2,675,030
Taxes payable	570,631	681,939
Accrued liabilities	800,558	679,350
Total current liabilities	44,010,342	40,012,424
Purchase option and warrants liability	297,466	496,217
Total liabilities	44,307,808	40,508,641
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Common stock; $0.001 par value; 250,000,000 shares authorized; 25,214,678 and 25,214,678 shares issued and outstanding as of September 30, 2017 and March 31, 2017	25,215	25,215
Preferred stock; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as of September 30, 2017 and March 31, 2017
Additional paid-in capital	37,270,620	36,581,248
Statutory reserves	1,309,109	1,309,109
Accumulated deficit	(15,189,270)	(12,601,257)
Accumulated other comprehensive income	2,442,315	1,350,062
Total stockholders' equity	25,857,989	26,664,377
Total liabilities and stockholders' equity	$ 70,165,797	$ 67,173,018

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Sep. 30, 2017	Mar. 31, 2017
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	25,214,678	25,214,678
Common stock, shares outstanding	25,214,678	25,214,678
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
REVENUES, NET	$ 23,491,043	$ 20,160,835	$ 45,161,411	$ 41,096,750
COST OF GOODS SOLD	17,933,446	15,807,828	35,426,153	32,261,939
GROSS PROFIT	5,557,597	4,353,007	9,735,258	8,834,811
SELLING EXPENSES	4,350,772	3,023,322	8,267,631	5,706,043
GENERAL AND ADMINISTRATIVE EXPENSES	2,855,555	1,382,650	4,580,998	3,301,132
TOTAL OPERATING EXPENSES	7,206,327	4,405,972	12,848,629	9,007,175
(LOSS) FROM OPERATIONS	(1,648,730)	(52,965)	(3,113,371)	(172,364)
INTEREST INCOME	358,344	61,035	403,243	285,457
INTEREST EXPENSE		(430)		(869)
OTHER INCOME(LOSS), NET	(8,703)	17,425	(38,051)	104,624
CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITIES	148,427	90,289	198,751	58,093
(LOSS) INCOME BEFORE INCOME TAXES	(1,150,662)	115,354	(2,549,428)	274,941
PROVISION FOR INCOME TAXES	18,047	17,484	38,585	49,518
NET (LOSS) INCOME	(1,168,709)	97,870	(2,588,013)	229,023
OTHER COMPREHENSIVE (LOSS) INCOME
Foreign currency translation adjustments	633,184	(87,721)	1,092,253	27,148
COMPREHENSIVE (LOSS) INCOME	$ (535,525)	$ 10,149	$ (1,495,760)	$ 256,171
WEIGHTED AVERAGE NUMBER OF SHARES:
Basic	25,214,678	19,375,773	25,214,678	18,239,065
Diluted	25,214,678	19,375,773	25,214,678	18,239,065
EARNINGS PER SHARES:
Basic	$ (0.05)	$ 0.01	$ (0.10)	$ 0.01
Diluted	$ (0.05)	$ 0.01	$ (0.10)	$ 0.01

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ (2,588,013)	$ 229,023
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization	590,618	466,570
Stock-based compensation	689,372	1,329,574
Bad debt provision	1,241,159	(177,274)
Change in fair value of purchase option derivative liability	(198,751)	(58,145)
Change in operating assets:
Accounts receivable, trade	(2,138,968)	(2,190,470)
Notes receivable	(49,387)	(156,527)
Inventories	(789,355)	(3,358,110)
Other receivables	(39,756)	(176,334)
Advances to suppliers	958,032	275,098
Other current assets	(180,048)	(269,040)
Other noncurrent assets	(106,981)	(354,594)
Long term deposit	(813,282)
Change in operating liabilities:
Accounts payable, trade	2,911,679	5,147,686
Other payables and accrued liabilities	(181,932)	(102,920)
Customer deposits	308,252	156,632
Taxes payable	(133,285)	(306,109)
Net cash (used in) provided by operating activities	(520,646)	455,060
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(212,358)	(49,298)
Purchase of financial assets available for sale	(73,915)
Increase in construction-in-progress	(473,716)
Increase intangible assets	(298,617)
Decrease in Financial assets available for sale		454,608
Investment in a joint venture	(9,387)	(75,768)
Additions to leasehold improvements	(27,986)	(26,262)
Net cash provided by investing activities	(1,095,979)	303,280
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from short-term bank loan
Repayment of short-term bank loan
Change in restricted cash	(503,908)	6,411,257
Repayments of notes payable	(12,929,115)	(17,196,298)
Proceeds from notes payable	12,664,216	11,800,003
Proceeds from other payables-related parties		95,088
Repayment of other payables-related parties	(88,698)
Proceeds from equity financing
Net cash provided by financing activities	(857,505)	1,110,050
EFFECT OF EXCHANGE RATE ON CASH	947,579	(188,172)
INCREASE IN CASH	(1,526,551)	1,680,218
CASH, beginning of period	18,364,424	6,671,873
CASH, end of period	16,837,873	8,352,091
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest		869
Cash paid for income taxes	$ 42,689	$ 42,437

Description of Business and Org

Description of Business and Organization	6 Months Ended
	Sep. 30, 2017
Description of Business and Organization [Abstract]
DESCRIPTION OF BUSINESS AND ORGANIZATION	Note 1 – DESCRIPTION OF BUSINESS AND ORGANIZATION China Jo-Jo Drugstores, Inc. (“Jo-Jo Drugstores” or the “Company”), was incorporated in Nevada on December 19, 2006, originally under the name “Kerrisdale Mining Corporation”. On September 24, 2009, the Company changed its name to “China Jo-Jo Drugstores, Inc.” in connection with a share exchange transaction as described below. On September 17, 2009, the Company completed a share exchange transaction with Renovation Investment (Hong Kong) Co., Ltd. (“Renovation”), whereby 7,900,000 shares of common stock were issued to the stockholders of Renovation in exchange for 100% of the capital stock of Renovation. The completion of the share exchange transaction resulted in a change of control. The share exchange transaction was accounted for as a reverse acquisition and recapitalization and, as a result, the consolidated financial statements of the Company (the legal acquirer) are, in substance, those of Renovation (the accounting acquirer), with the assets and liabilities, and revenues and expenses, of the Company being included effective from the date of the share exchange transaction. Renovation has no substantive operations of its own except for its holdings of Zhejiang Jiuxin Investment Management Co., Ltd. (“Jiuxin Management”), Zhejiang Shouantang Medical Technology Co., Ltd. (“Shouantang Technology”), Hangzhou Jiutong Medical Technology Co., Ltd (“Jiutong Medical”), and Hangzhou Jiuyi Medical Technology Co. Ltd. (“Jiuyi Technology”), its wholly-owned subsidiaries. The Company is an online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products in the People’s Republic of China (“China” or the “PRC”). The Company’s offline retail business is comprised primarily of pharmacies, which are operated by Hangzhou Jiuzhou Grand Pharmacy Chain Co., Ltd. (“Jiuzhou Pharmacy”), a company that the Company controls through contractual arrangements. On March 31, 2017, Jiuxin Management established a subsidiary, Lin’An Jiuzhou Pharmacy Co., Ltd (“Lin’An Jiuzhou”) to operates drugstores in Lin’an City. During the six months ending September 30, 2017, Jiuzhou Pharmacy established the following companies, each of which operates a drugstore in Hangzhou City: Entity Name Date Established Hangzhou Jiuben Pharmacy Co., Ltd (“Jiuben Pharmacy”) April 27, 2017 Hangzhou Jiuli Pharmacy Co., Ltd (“Jiuli Pharmacy”) May 22, 2017 Hangzhou Jiuxiang Pharmacy Co., Ltd (“Jiuxiang Pharmacy”) May 26, 2017 Hangzhou Jiuheng Pharmacy Co., Ltd (“Jiuheng Pharmacy”) June 6, 2017 Hangzhou Jiujiu Pharmacy Co., Ltd (“Jiujiu Pharmacy”) June 8, 2017 Hangzhou Jiuyi Pharmacy Co., Ltd (“Jiuyi Pharmacy”) June 8, 2017 Hangzhou Jiuyuan Pharmacy Co., Ltd (“Jiuyuan Pharmacy”) July 13, 2017 Hangzhou Jiumu Pharmacy Co., Ltd (“Jiumu Pharmacy”) July 21, 2017 Hangzhou Jiurui Pharmacy Co., Ltd (“Jiurui Pharmacy”) August 4, 2017 The Company’s offline retail business also includes three medical clinics through Hangzhou Jiuzhou Clinic of Integrated Traditional and Western Medicine (“Jiuzhou Clinic”) and Hangzhou Jiuzhou Medical and Public Health Service Co., Ltd. (“Jiuzhou Service”), both of which are also controlled by the Company through contractual arrangements. On December 18, 2013, Jiuzhou Service established, and held 51% of, Hangzhou Shouantang Health Management Co., Ltd. (“Shouantang Health”), a PRC company licensed to sell health care products. Shouantang Health was closed in April 2015. In May 2016, Hangzhou Shouantang Bio-technology Co., Ltd. (“Shouantang Bio”), a wholly-owned subsidiary of Shouantang Technology, set up and held 49% of Hangzhou Kahamadi Bio-technology Co., Ltd.(“Kahamadi Bio”), a joint venture specialized in brand name development for nutritional supplements. The Company currently conducts its online retail pharmacy business through Jiuzhou Pharmacy, which holds the Company’s online pharmacy license. Prior to November 2015, the Company primarily conducted its online retail pharmacy business through Zhejiang Quannuo Internet Technology Co., Ltd. (“Quannuo Technology”). In May 2015, the Company established Zhejiang Jianshun Network Technology Co. Ltd, a joint venture with Shanghai Jianbao Technology Co., Ltd. (“Jianshun Network”), in order to develop its online pharmaceutical sales from large commercial medical insurance companies. On September 10, 2015, Renovation set up a new entity Jiuyi Technology to provide additional technical support such as webpage development to our online pharmacy business. In November 2015, the Company sold all of the equity interests of Quannou Technology to six individuals for approximately $17,121 (RMB107,074). After the sale, its technical support function has been transferred back to Jiuzhou Pharmacy, which hosts our online pharmacy. The Company’s wholesale business is primarily conducted through Zhejiang Jiuxin Medicine Co., Ltd. (“Jiuxin Medicine”), which is licensed to distribute prescription and non-prescription pharmaceutical products throughout China. Jiuzhou Pharmacy acquired Jiuxin Medicine on August 25, 2011. The Company’s herb farming business is conducted by Hangzhou Qianhong Agriculture Development Co., Ltd. (“Qianhong Agriculture”), a wholly-owned subsidiary of Jiuxin Management, which operates a cultivation project of herbal plants used for traditional Chinese medicine (“TCM”). The accompanying consolidated financial statements reflect the activities of the Company and each of the following entities: Entity Name Background Ownership Renovation ● Incorporated in Hong Kong SAR on September 2, 2008 100% Jiuxin Management ● Established in the PRC on October 14, 2008 100% ● Deemed a wholly foreign owned enterprise (“WFOE”) under PRC law ● Registered capital of $14.5 million fully paid Shouantang Technology ● Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million 100% ● Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid ● Deemed a WFOE under PRC law ● Invests and finances the working capital of Quannuo Technology Qianhong Agriculture ● Established in the PRC on August 10, 2010 by Jiuxin Management 100% ● Registered capital of RMB 10 million fully paid ● Carries out herb farming business Jiuzhou Pharmacy (1) ● Established in the PRC on September 9, 2003 VIE by contractual arrangements (2) ● Registered capital of RMB 5 million fully paid ● Operates the “Jiuzhou Grand Pharmacy” stores in Hangzhou Jiuzhou Clinic (1) ● Established in the PRC as a general partnership on October 10, 2003 VIE by contractual arrangements (2) ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores Jiuzhou Service (1) ● Established in the PRC on November 2, 2005 VIE by contractual arrangements (2) ● Registered capital of RMB 500,000 fully paid ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores Jiuxin Medicine ● Established in PRC on December 31, 2003 VIE by contractual arrangements ● Acquired by Jiuzhou Pharmacy in August 2011 as a wholly-owned subsidiary of ● Registered capital of RMB 10 million fully paid Jiuzhou Pharmacy (2) ● Carries out pharmaceutical distribution services Jiutong Medical ● Established in the PRC on December 20, 2011 by Renovation 100% ● Registered capital of $2.6 million fully paid ● Currently has no operation Entity Name Background Ownership Shouantang Bio ● Established in the PRC in October, 2014 by Shouantang Technology 100% ● 100% held by Shouantang Technology ● Registered capital of RMB 1,000,000 fully paid ● Sells nutritional supplements under its own brand name Jiuyi Technology ● Established in the PRC on September 10, 2015 100% ● 100% held by Renovation ● Registered capital of USD 5,000,000 (USD 2,500,000 paid) ● Technical support to online pharmacy Kahamadi Bio ● Established in the PRC in May 2016 49% ● 49% held by Shouantang Bio ● Registered capital of RMB 10 million ● Develop brand name for nutritional supplements Lin’An Jiuzhou ● Established in the PRC in March 31, 2017 100% ● 100% held by Jiuxin Management ● Registered capital of RMB 5 million (RMB 550,000 paid) ● Explore retail pharmacy market in Lin’An City Jiuben Pharmacy ● Established in the PRC in April 27, 2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City Jiumu Pharmacy ● Established in the PRC in July 21, 2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City Jiuheng Pharmacy ● Established in the PRC in June 6, 2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City Jiujiu Pharmacy ● Established in the PRC in June 8, 2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City Jiuli Pharmacy ● Established in the PRC in May 22 ,2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City Jiurui Pharmacy ● Established in the PRC in August 4, 2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City JiuxiangPharmacy ● Established in the PRC in May 26, 2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City Entity Name Background Ownership Jiuyi Pharmacy ● Established in the PRC in June 8, 2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City Jiuyuan Pharmacy ● Established in the PRC in July 13, 2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City (1) Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service have been under the common control of Mr. Lei Liu, Mr. Chong’an Jin and Ms. Li Qi, the three shareholders of Renovation (the “Owners”) since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting rights agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company’s respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy. (2) To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity (“VIE”) under the accounting standards of the Financial Accounting Standards Board (“FASB”). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiary under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2017
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation and consolidation The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries and VIEs. All significant inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation. Consolidation of variable interest entities In accordance with accounting standards regarding consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary is required to consolidate the VIE for financial reporting purposes. The Company has concluded, based on the contractual arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each a VIE and that the Company’s wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual returns. Additionally, as Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service are under common control, the consolidated financial statements have been prepared as if the transactions had occurred retroactively as to the beginning of the reporting period of these consolidated financial statements. Control and common control are defined under the accounting standards as “an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership interest of each entity.” Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized in the voting rights agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly, the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin Management, in turn, is owned by Renovation, which is owned by the Company. Risks and Uncertainties The operations of the Company are located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s operations in the PRC are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results. The Company has significant cash deposits with suppliers in order to obtain and maintain inventory. The Company’s ability to obtain products and maintain inventory at existing and new locations is dependent upon its ability to post and maintain significant cash deposits with its suppliers. In the PRC, many vendors are unwilling to extend credit terms for product sales that require cash deposits to be made. The Company does not generally receive interest on any of its supplier deposits, and such deposits are subject to loss as a result of the creditworthiness or bankruptcy of the party who holds such funds, as well as the risk from illegal acts such as conversion, fraud, theft or dishonesty associated with the third party. If these circumstances were to arise, the Company would find it difficult or impossible, due to the unpredictability of legal proceedings in China, to recover all or a portion of the amount on deposit with its suppliers. Members of the current management team own controlling interests in the Company and are also the Owners of the VIEs in the PRC. The Company only controls the VIEs through contractual arrangements which obligate it to absorb the risk of loss and to receive the residual expected returns. As such, the controlling shareholders of the Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the Company would not retain control of the VIEs. Use of estimates The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The significant estimates made in the preparation of the accompanying unaudited condensed consolidated financial statements relate to the assessment of the carrying values of accounts receivable, advances to suppliers and related allowance for doubtful accounts, useful lives of property and equipment, inventory reserve and fair value of its purchase option derivative liability. Because of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates. Fair value measurements The Company has adopted FASB ASC Topic 820, “Fair Value Measurement and Disclosure,” which defines fair value, establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. It does not require any new fair value measurements, but provides guidance on how to measure fair value by providing a fair value hierarchy used to classify the source of the information. It establishes a three-level valuation hierarchy of valuation techniques based on observable and unobservable inputs, which may be used to measure fair value and include the following: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Classification within the hierarchy is determined based on the lowest level of input that is significant to the fair value measurement. The Company’s financial assets and liabilities, which include financial instruments as defined by FASB ASC 820, include cash and cash equivalents, accounts receivable, accounts payable, long-term debt and derivatives. The carrying amounts of cash and cash equivalents, financial assets available for sales, accounts receivable, notes receivables, and accounts payable are a reasonable approximation of fair value due to the short maturities of these instruments (Level 1). The carrying amount of notes payable approximates fair value based on borrowing rates of similar bank loan currently available to the Company (Level 2) (See Note 13). The carrying amount of the Company’s derivative instruments is recorded at fair value and is determined based on observable inputs that are corroborated by market data (Level 2). As of September 30, 2017, the fair values of our derivative instruments that were carried at fair value (See Note 17). Active Market Observable Unobservable Total Cash and cash equivalents 16,837,873 - $ - 16,837,873 Notes payable - 12,872,045 - 12,872,045 Warrants liability - 297,466 $ - 297,466 Total 16,837,873 13,169,511 $ - 30,007,384 Revenue recognition Revenue from sales of prescription medicine at drugstores is recognized when the prescription is filled and the customer picks up and pays for the prescription. Revenue from sales of other merchandise at drugstores is recognized at the point of sale, which is when a customer pays for and receives the merchandise. Usually the majority of our merchandise, such as prescription and OTC drugs, are not allowed to be returned after the customers leave the counter. Return of other products, such as sundry products, are minimal. Sales of drugs reimbursed by the local government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. Based on historical experience, a reserve for potential loss from denial of reimbursement on certain unqualified drugs is made to the receivables from the government agency. Revenue from medical services is recognized after the service has been rendered to a customer. Revenue from online pharmacy sales is recognized when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer’s location. Any loss caused in a shipment will be reimbursed by the Company’s courier company. Our sales policy allows for the return of certain merchandises without reason within seven days after customer’s receipt of the applicable merchandise. A proper sales reserve is made to account for the potential loss from returns from customers. Historically, sales returns seven days after merchandise receipts have been minimal. Revenue from sales of merchandise to non-retail customers is recognized when the following conditions are met: (1) persuasive evidence of an arrangement exists (sales agreements and customer purchase orders are used to determine the existence of an arrangement); (2) delivery of goods has occurred and risks and benefits of ownership have been transferred, which is when the goods are received by the customer at its designated location in accordance with the sales terms; (3) the sales price is fixed or determinable; and (4) collectability is probable. Historically, sales returns have been minimal. The Company’s revenue is net of value added tax (“VAT”) collected on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities. Restricted cash The Company’s restricted cash consists of cash and long-term deposits in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset. Accounts receivable Accounts receivable represents the following: (1) amounts due from banks relating to retail sales that are paid or settled by the customers’ debit or credit cards, (2) amounts due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine, and medical services that are paid or settled by the customers’ medical insurance cards, (3) amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce platforms and (4) amounts due from non-retail customers for sales of merchandise. Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as necessary. In the Company’s retail business, accounts receivable mainly consist of reimbursements due from the government insurance bureaus and commercial health insurance programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which it determines to be uncollectible after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated reserves on related outstanding accounts receivable based on historical trends. In the Company’s online pharmacy business, accounts receivable primarily consist of amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce platforms. To purchase pharmaceutical products from an e-commerce platforms such as Tmall, customers are required to submit payment to certain non-bank third party payment instruments, such as Alipay, which, in turn, reimburse the Company within seven days to a month. Except for customer returns of sold products, the receivables from these payments instruments are rarely uncollectible. In its wholesale business, the Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, bad debt percentages are determined by management, based on historical experience and the current economic climate, are applied to customers’ balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate. Advances to suppliers Advances to suppliers consist of prepayments to our vendors, such as pharmaceutical manufacturers and other distributors. Since the acquisition of Jiuxin Medicine, we have transferred almost all logistics services of our retail drugstores to Jiuxin Medicine. Jiuzhou Pharmacy only directly purchases certain non-medical products, such as certain nutritional supplements. As a result, almost all advances to suppliers are made by Jiuxin Medicine. Advances to suppliers for our drug wholesale business consist of prepayments to our vendors, such as pharmaceutical manufacturers and other distributors. We typically receive products from vendors within three to nine months after making prepayments. We continuously monitor delivery from, and payments to, our vendors while maintaining a provision for estimated credit losses based upon historical experience and any specific supplier issues, such as discontinuing of inventory supply, that have been identified. If we have difficulty receiving products from a vendor, we take the following steps: cease purchasing products from such vendor, ask for return of our prepayment promptly, and if necessary, take legal action. If all of these steps are unsuccessful, management then determines whether the prepayments should be reserved or written off. Inventories Inventories are stated at the lower of cost or market value. Cost is determined using the first in first out (FIFO) method. Market value is the lower of replacement cost or net realizable value. The Company carries out physical inventory counts on a monthly basis at each store and warehouse location. Herbs that the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development cost. All costs are accumulated until the time of harvest and then allocated to harvested herbs costs when the herbs are sold. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses and damaged merchandise that are identified. The Company provides a reserve for estimated inventory obsolescence or excess quantities on hand equal to the difference, if any, between the cost of the inventory and its estimated realizable value. Farmland assets Herbs that the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, and labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development costs. Since April 2014, amortization of farmland development costs has been expensed instead of allocated into inventory due to unpredictable future market value of planted gingko trees. All related costs described in the above are accumulated until the time of harvest and then allocated to harvested herbs when they are sold. Property and equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets, taking into consideration the assets’ estimated residual value. Leasehold improvements are amortized over the shorter of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company’s property and equipment: Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years Maintenance, repairs and minor renewals are charged to expenses as incurred. Major additions and betterment to property and equipment are capitalized. Intangible assets Intangible assets are acquired individually or as part of a group of assets, and are initially recorded at their fair value. The cost of a group of assets acquired in a transaction is allocated to the individual assets based on their relative fair values. The estimated useful lives of the Company’s intangible assets are as follows: Estimated Land use rights 50 years Software 3 years The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets might be impaired. Impairment of long lived assets The Company evaluates long lived tangible and intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. Recoverability is measured by comparing the assets’ net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss. There were no fixed assets and farmland assets impaired for the three months ended September 30, 2017. Notes payable During the normal course of business, the Company regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short maturity period of six to nine months. Income taxes The Company follows FASB ASC Topic 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company has adopted FASB ASC Topic 740-10-25, which provides criteria for the recognition, measurement, presentation and disclosure of uncertain tax position. The Company must recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. The Company performed a self-assessment and the Company’s liability for income taxes includes liability for unrecognized tax benefits, interest and penalties which relate to tax years still subject to review by taxing authorities. Audit periods remain open for review until the statute of limitations has passed, which in the PRC is usually 5 years. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2017 and March 31, 2017, the management of the Company considered that the Company had no additional liabilities for uncertain tax positions affecting its consolidated financial position and results of operations or cash flows, and will continue to evaluate for any uncertain position in the future. There are no estimated interest costs and penalties provided in the Company’s consolidated financial statements for the three months ended September 30, 2017 and 2016, respectively. The Company’s tax positions related to open tax years are subject to examination by the relevant tax authorities, the most significant of which is the China Tax Authority. Value added tax Sales revenue represents the invoiced value of goods, net of VAT. All of the Company’s products are sold in the PRC and are subject to a VAT on the gross sales price. The VAT rates range up to 17%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable net of payments in the accompanying financial statements. The accounting standards clarify the accounting and disclosure requirements for uncertain tax positions and prescribe a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. The accounting standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. No significant penalties, uncertain tax provisions or interest relating to income taxes were incurred during the periods ended September 30, 2017 and 2016. Stock based compensation The Company follows the provisions of FASB ASC 718, “Compensation — Stock Compensation,” which establishes accounting standards for non-employee and employee stock-based awards. Under the provisions of FASB ASC 718, the fair value of stock issued is used to measure the fair value of services received as the Company believes such approach is a more reliable method of measuring the fair value of the services. For non-employee stock-based awards, fair value is measured based on the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is calculated and then recognized as compensation expense over the requisite performance period. For employee stock-based awards, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense with graded vesting on a straight–line basis over the requisite service period for the entire award. Advertising and promotion costs Advertising and promotion costs are expensed as incurred and amounted to $180,639 and $113,638 for the three months ended September 30, 2017 and 2016, respectively, and $320,734 and $182,487 for the six months ended September 30, 2017 and 2016, respectively. Such costs consist primarily of print and promotional materials such as flyers to local communities. Operating leases The Company leases premises for retail drugstores, offices and wholesale warehouse under non-cancellable operating leases. Operating lease payments are expensed over the term of lease. A majority of the Company’s retail drugstore leases have a 3 to 10 year term with a renewal option upon the expiration of the lease; the wholesale warehouse lease has a 10-year term with a renewal option upon the expiration of the lease. The Company has historically been able to renew a majority of its drugstores leases. Under the terms of the lease agreements, the Company has no legal or contractual asset retirement obligations at the end of the lease. In addition, land leased from the government is amortized on a straight-line basis over a 30-year term. Foreign currency translation The Company uses the United States dollar (“U.S. dollars” or “USD”) for financial reporting purposes. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency the Renminbi (“RMB”), the currency of the PRC. In general, for consolidation purposes, the Company translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income. The balance sheet amounts, with the exception of equity, at September 30, 2017 and at March 31, 2017 were translated at 1 RMB to 0.1503 USD and at 1 RMB to 0.1451 USD, respectively. The average translation rates applied to income and cash flow statement amounts for the six months ended September 30, 2017 and 2016 were at at 1 RMB to 0.1478 USD and 1 RMB to 0.1515 USD, respectively. Concentrations and credit risk Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash and restricted cash. The Company has cash balances at financial institutions located in Hong Kong and PRC. Balances at financial institutions in Hong Kong may, from time to time, exceed Hong Kong Deposit Protection Board’s insured limits. Since March 31, 2015, balances at financial institutions and state-owned banks within the PRC are covered by insurance up to RMB 500,000 (USD 77,150) per bank. As of September 30, 2017 and March 31, 2017, the Company had deposits totaling $26,709,868 and $27,357,785 that were covered by such limited insurance, respectively. Any balance over RMB 500,000 (USD 75,150) per bank in PRC will not be covered. To date, the Company has not experienced any losses in such accounts. For the three months ended September 30, 2017, three largest vendors accounted for 61.3% of the Company’s total purchases and one vendor accounted for 16.8% of the Company’s total advances to suppliers. For the three months ended September 30, 2016, one largest vendor accounted for 30.7% of the Company’s total purchases and one vendor accounted for 9.9% of the Company’s total advances to suppliers. For the six months ended September 30, 2017, two largest vendors accounted for 39.6% of the Company’s total purchases and one vendor accounted for 16.8% of the Company’s total advances to suppliers. For the six months ended September 30, 2016, two largest vendors accounted for 38.6% of the Company’s total purchases and one vendor accounted for 9.9% of the Company’s total advances to suppliers. For the three months and six months ended September 30, 2017 and September 30, 2016, no customer accounted for more than 10% of the Company’s total sales or accounts receivable. Recent Accounting Pronouncements In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, “Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which removes Step 2 from the goodwill impairment test. An entity will apply a one-step quantitative test and record the amount of goodwill impairment as the excess of a reporting unit’s carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The new guidance does not amend the optional qualitative assessment of goodwill impairment. Public business entity that is a U.S. Securities and Exchange Commission filer should adopt the amendments in this ASU for its annual or any interim goodwill impairment test in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact of the adoption of ASU 2017-04 on our consolidated financial statements. Revenue Recognition In March 2016, the FASB issued ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Gross versus Net),” clarifying the principal versus agent guidance in the new revenue recognition standard, by revising the indicators to focus on evidence that the Company is a principal. In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” reducing the complexity when applying the guidance for identifying performance obligations and clarifying how to determine whether revenue related to a performance obligation for an intellectual property license is recognized over time or at a point in time. In May 2016, the FASB issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients,” clarifying certain core recognition principles including collectability, sales tax presentation, noncash consideration, contract modifications and completed contracts at transition. These ASUs are effective for the Company beginning in the first quarter of the fiscal year of 2019, allow for early adoption in the first quarter of 2017 and may be applied using either a full retrospective approach or a modified retrospective approach. The Company is planning to adopt the new accounting standard ASC 606 and all related amendment using a modified retrospective approach. Revenue from sales at drugstores continues to be recognized at the point of sale, which is when a customer pays for and receives the merchandise. Revenue from online pharmacy sales is recognized when merchandise is shipped to customers. Revenue from sales of merchandise to non-retail customers is recognized upon delivery of goods. The Company does not expect the adoption of the New Revenue Standard to have material impact on its net income on an ongoing basis. Its interpretation is subject to change as a result of future change in market conditions or product offering.

Financial Assets Available for

Financial Assets Available for Sale	6 Months Ended
	Sep. 30, 2017
Financial Assets Available for Sale [Abstract]
FINANCIAL ASSETS AVAILABLE FOR SALE	NOTE 3 – FINANCIAL ASSETS AVAILABLE FOR SALE As of September 30, 2017 and March 31, 2017, financial assets available for sale amounted to $165,282 (RMB 1,100,000) and $87,068 (RMB 600,000), respectively. In the year ended March 31, 2017, the Company invested as a limited partner (LP) in a private equity fund, which is intended to invest in retail pharmaceutical business. The company has signed an investment agreement with the private equity fund and agreed to invest a total of $300,600 (RMB 2,000,000).

Trade Accounts Receivable

Trade Accounts Receivable	6 Months Ended
	Sep. 30, 2017
Trade Accounts Receivable/Other Receivable [Abstract]
TRADE ACCOUNTS RECEIVABLE	NOTE 4 – TRADE ACCOUNTS RECEIVABLE Trade accounts receivable consisted of the following: September 30, March 31, Accounts receivable $ 12,270,651 $ 9,977,101 Less: allowance for doubtful accounts (2,070,109 ) (1,415,505 ) Trade accounts receivable, net $ 10,200,542 $ 8,561,596 For the three months ended September 30, 2017 and 2016, $98,590 and $30,790 in accounts receivable were directly written off respectively. For the six months ended September 30, 2017 and 2016, $124,983 and $63,382 in accounts receivable were directly written off respectively. As of September 30, 2017 and March 31, 2017, no trade accounts receivables were pledged as collateral for borrowings from financial institutions.

Other Receivable

Other Receivable	6 Months Ended
	Sep. 30, 2017
Trade Accounts Receivable/Other Receivable [Abstract]
OTHER RECEIVABLE	Note 5 – OTHER RECEIVABLE Other receivable consisted of the following: September 30, March 31, Deposit* $ 1,216,800 $ 855,755 Advance to employees 584,996 652,436 Accrued supplier rebate** 190,554 321,993 Interest receivable*** 240,410 Others 418,825 465,593 Less: allowance for doubtful accounts (27,526 ) (26,584 ) Other receivable, net $ 2,624,059 $ 2,269,193 * It refers to various advances deposits made to service providers and commercial platforms such as Alibaba’s Tmall, in order to carry business via these service providers and platforms. ** It refers to supplier rebate receivables, which are computed based on our sales volume of the suppliers’ products. *** It refers to accrued interest receivable from several three-year bank deposits, which are used as a pledge for bank-guranteed notes payable (see Note 14).

Other Current Assets

Other Current Assets	6 Months Ended
	Sep. 30, 2017
Other Current Assets [Abstract]
OTHER CURRENT ASSETS	Note 6 – OTHER CURRENT ASSETS Other current assets consisted of the following: September 30 March 31, Prepaid rental expenses (1) $ 1,395,985 $ 1,171,472 Prepaid and other current assets 408,669 394,683 Total $ 1,804,654 $ 1,566,155 (1) Represents store and office rental expenses that were usually prepaid and amortized over the prepayment period. The increase reflects additional prepaid rental for new stores.

Property and Equipment

Property and Equipment	6 Months Ended
	Sep. 30, 2017
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	Note 7 – PROPERTY AND EQUIPMENT Property and equipment consisted of the following: September 30, March 31, Building $ 1,611,055 $ 1,555,923 Leasehold improvements 12,229,600 11,783,611 Farmland development cost 1,796,971 1,735,475 Office equipment and furniture 5,126,811 5,339,005 Motor vehicles 475,446 585,769 Total 21,239,883 20,999,783 Less: Accumulated depreciation (14,861,284 ) (14,489,479 ) Impairment* (2,365,317 ) (2,247,147 ) Construction-in-progress** 520,108 - Property and equipment, net $ 4,533,390 $ 4,263,157 * The variance of impairment from March 31, 2017 to September 30, 2017 is solely caused by exchange rate variance. ** Includes clinic renovation expense of $70,798 and SAP (a popular ERP software) implementation fee of $449,309. The clinic renovation has been completed at the end of October 2017. SAP system is expected to be implemented by the end of 2017. Depreciation expenses for property and equipment totaled $171,051 and $213,969 for the three months ended September 30, 2017 and 2016, respectively. Depreciation expenses for property and equipment totaled $576,154 and $452,979 for the six months ended September 30, 2017 and 2016, respectively. There were no fixed assets impaired in the six months ended September 30, 2017. For the year ended March 31, 2017, $106,257 of land and road improvement in Qianhong Agriculture were impaired due to the estimated fair value being lower than the carrying value.

Advances to Suppliers

Advances to Suppliers	6 Months Ended
	Sep. 30, 2017
Advances to Suppliers [Abstract]
ADVANCES TO SUPPLIERS	Note 8 – ADVANCES TO SUPPLIERS Advances to suppliers consist of deposits, with or advances to, outside vendors for future inventory purchases. Most of the Company’s suppliers require a certain amount of money to be deposited with them as a guarantee that the Company will receive its purchase on a timely basis. This amount is refundable and bears no interest. As of September 30, 2017 and March 31, 2017, advance to suppliers consist of the following: September 30, March 31, Advance to suppliers $ 6,280,908 $ 7,006,396 Less: allowance for doubtful accounts (2,366,809 ) (1,502,255 ) Advance to suppliers, net $ 3,914,099 $ 5,504,141 * In order to collect a larger rebate for certain merchandise, such as Colla corii asini For the six months ended September 30, 2017 and 2016, none of the advances to suppliers were written off against previous allowances for doubtful accounts, respectively.

Inventory

Inventory	6 Months Ended
	Sep. 30, 2017
Inventory [Abstract]
INVENTORY	Note 9 – INVENTORY Inventory consisted of finished goods, valued at $11,077,027 and $9,923,101 as of September 30, 2017 and March 31, 2017, respectively. The Company constantly monitors its potential obsolete products and is allowed to return products close to their expiration date to its suppliers. Any loss on damaged items is immaterial and will be recognized immediately. As a result, no reserves were made for inventory as of September 30, 2017 and March 31, 2017.

Farmland Assets

Farmland Assets	6 Months Ended
	Sep. 30, 2017
Farmland Assets [Abstract]
FARMLAND ASSETS	Note 10 – FARMLAND ASSETS Farmland assets consist of ginkgo trees planted in 2012 and expected to be harvested and sold in several years. As of September 30, 2017 and March 31, 2017, farmland assets are valued as follows: September 30, March 31, 2017 2017 Farmland assets $ 2,273,593 $ 2,195,787 Less: Impairment* (1,529,337 ) (1,477,000 ) Farmland assets, net $ 744,256 $ 718,787 * The estimated fair value is estimated to be lower than its investment value as of September 30, 2017 and March 31, 2017.

Long Term Deposits, Landlords

Long Term Deposits, Landlords	6 Months Ended
	Sep. 30, 2017
Long Term Deposits, Landlords [Abstract]
LONG TERM DEPOSITS, LANDLORDS	Note 11 – LONG TERM DEPOSITS, LANDLORDS As of September 30, 2017 and March 31, 2017, long term deposits amounted to $3,202,793 and $2,294,848, respectively. Long term deposits are money deposited with, or advanced to, landlords for the purpose of securing retail store leases that the Company does not anticipate being returned within the next twelve months. Most of the Company’s landlords require a minimum payment of nine months’ rent, paid upfront, plus additional deposits. In the six months ended September 30, 2017, in order to quickly expand its network, the Company signed quite a few new store lease agreements and made additional leasehold deposits.

Other Noncurrent Assets

Other Noncurrent Assets	6 Months Ended
	Sep. 30, 2017
Other Noncurrent Assets [Abstract]
OTHER NONCURRENT ASSETS	Note 12 – OTHER NONCURRENT ASSETS Other noncurrent assets consisted of the following: September 30, March 31, Forest land use rights* $ 1,192,217 $ 1,177,005 Long-term prepaid store rent (over one year)** 135,230 - Total $ 1,327,447 $ 1,177,005 * The prepayment for lease of forest land use rights is a payment made to a local government in connection with entering into an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060. The amortization of the prepayment for the lease of forest land use right was approximately $7,042 and $15,484 for the three months ended September 30, 2017 and 2016, respectively. The amortization of the prepayment for the lease of forest land use right was approximately $13,888 and $31,298 for the six months ended September 30, 2017 and 2016, respectively. The Company’s amortizations of the prepayment for lease of land use right for the next five years and thereafter are as follows: For the year ending September 30, Amount 2018 $ 28,233 2019 28,233 2020 28,233 2021 28,233 2022 28,233 Thereafter 1,057,869 ** In order to secure better terms in a lease agreement, the Company agreed to pay two-year rent at the beginning of the lease.

Intangible Assets

Intangible Assets	6 Months Ended
	Sep. 30, 2017
Intangible Assets [Abstract]
INTANGIBLE ASSETS	Note 13 – INTANGIBLE ASSETS Net intangible assets consisted of the following at: September 30, March 31, License (1) $ 1,747,477 $ 1,394,546 Land use rights (2) 1,465,229 1,415,086 Total intangible assets 3,212,706 2,809,632 Less: accumulated amortization (115,160 ) (97,021 ) Intangible assets, net $ 3,097,546 $ 2,712,611 Amortization expense of intangibles amounted to $7,334 and $6,101 for the three months ended September 30, 2017 and 2016, respectively, and $14,464 and $13,591 for the six months ended September 30, 2017 and 2016, respectively. (1) This represents the fair value of the licenses of insurance applicable drugstores acquired from Sanhao Pharmacy, a drugstore chain Jiuzhou Pharmacy acquired in 2014. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. The owners of these acquried drugstores agreed to cease their stores’ business and liquidate all of the stores’ accounts before Jiuzhou Pharmacy acquired their stores. As a result, Jiuzhou Pharmacy has not obtained any assets or liabilities from the stores, but was able to transfer the Certificate to our new store opened at the same time. (2) In July 2013, the Company purchased the land use rights of a plot of farmland in Lin’an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as our farming business in Lin’an has not grown, the Company does not expect completion of the plant in the near future.

Notes Payable

Notes Payable	6 Months Ended
	Sep. 30, 2017
Notes Payable [Abstract]
NOTES PAYABLE	Note 14 – NOTES PAYABLE The Company has credit facilities with Hangzhou United Bank (“HUB”), Bank of Hangzhou (“BOH”), Industrial and Commercial Bank of China (“ICBC”) and Zhejiang Tailong Commercial Bank (“ZTCB”) that provided working capital in the form of the following bank acceptance notes at September 30, 2017 and March 31, 2017: Origination Maturity September 30, March 31, Beneficiary Endorser date date 2017 2017 Jiuzhou Pharmacy (1) HUB 10/09/16 04/09/17 - 1,755,879 Jiuzhou Pharmacy (1) HUB 10/09/16 04/09/17 - 341,676 Jiuzhou Pharmacy (1) HUB 11/08/16 05/08/17 - 1,637,419 Jiuzhou Pharmacy (1) HUB 11/11/16 05/11/17 - 314,897 Jiuzhou Pharmacy (1) HUB 12/05/16 06/05/17 - 1,508,042 Jiuzhou Pharmacy (1) HUB 12/29/16 06/29/17 - 1,205,419 Jiuzhou Pharmacy (1) HUB 12/29/16 06/29/17 - 1,030,309 Jiuzhou Pharmacy (2) ZTCB 12/27/16 06/27/17 - 580,456 Jiuzhou Pharmacy (1) HUB 02/06/17 08/06/17 - 2,253,804 Jiuzhou Pharmacy (1) HUB 03/07/17 09/07/17 - 117,542 Jiuzhou Pharmacy (1) HUB 03/07/17 09/07/17 - 267,651 Jiuzhou Pharmacy (1) HUB 03/07/17 09/07/17 - 1,678,481 Jiuzhou Pharmacy (1) HUB 04/05/17 10/05/17 1,345,036 - Jiuzhou Pharmacy (1) HUB 05/04/17 11/04/17 1,806,808 - Jiuzhou Pharmacy (1) HUB 06/05/17 12/05/17 1,561,478 - Jiuzhou Pharmacy (1) HUB 06/05/17 12/05/17 354,534 - Jiuzhou Pharmacy (1) HUB 06/29/17 12/29/17 1,074,330 - Jiuzhou Pharmacy (1) HUB 06/29/17 12/29/17 826,408 - Jiuzhou Pharmacy (1) HUB 06/29/17 12/29/17 1,984,650 - Jiuzhou Pharmacy (1) HUB 08/09/17 02/09/18 1,357,600 - Jiuzhou Pharmacy (1) HUB 09/05/17 12/05/17 267,756 - Jiuzhou Pharmacy (1) HUB 09/05/17 03/05/18 2,293,445 - Total $ 12,872,045 $ 12,691,575 (1) As of March 31, 2017, the Company had $12,111,119 (RMB 81,459,343.5) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $1,328,098 (RMB 9,152,104.2) with HUB as collateral against these bank notes. As of September 30, 2017, the Company had $12,872,045 (RMB 85667428.6) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $1,432,935 (RMB 9,536,623) with HUB as collateral against these bank notes. Additionally, a total of $8,785,866 deposit (RMB 58,472,647.3) , which matures in three years, was deposited into HUB as a collateral for current and future notes payable from HUB. (2) As of March 31, 2017, the Company had $580,456 (RMB 4,000,000) of notes payable from ZTCB, with restricted cash in the amount of $290,228 (RMB 2,000,000) held at the bank. As of September 30, 2017, the Company had no notes payable from ZTCB. As of September 30, 2017, the Company had a credit line of approximately $16.74 million in the aggregate from HUB, BOH, ICBC and ZTCB. By putting up the restricted cash of $1.43 million deposited in the banks, the total credit line was $18.17 million. As of September 30, 2017, the Company had approximately $12.87 million of bank notes payable and approximately $5.30 million bank credit line was still available for further borrowing. The bank notes are secured by buildings owned by the Company’s major shareholders and by a shop of Jiuzhou Pharmacy, and are guaranteed by Jiuxin Medical.

Taxes

Taxes	6 Months Ended
	Sep. 30, 2017
Taxes [Abstract]
TAXES	Note 15 – TAXES Income tax For the three and six months ended September 30, 2017 and 2016, the income tax provisions were as follow: Three months ended Six months ended 2017 2016 2017 2016 Income tax $ 18,047 $ 17,484 $ 38,585 $ 45,918 The Company is subject to income taxes on an entity basis on income arising in or derived from the tax jurisdiction in which each entity is domiciled. Entity Income Tax Jurisdiction Jo-Jo Drugstores United States Renovation Hong Kong, PRC All other entities Mainland, PRC The following table reconciles the U.S. statutory tax rates with the Company’s effective tax rate for the three and six months ended September 30, 2017 and 2016: For the three months ended For the six months ended September 30, September 30, 2017 2016 2017 2016 U.S. Statutory rates 34 .0% 34 .0 % 34.0 % 34.0 % Foreign income not recognized in the U.S. (34.0 ) (34.0 ) (34.0 ) (34.0 ) China income taxes 25.0 25.0 25.0 25.0 Change in valuation allowance (1) (18 .4 ) (25.0 ) (2 2.9 ) (25.0 ) Non-deductible expenses-permanent difference (2) (8 .2 ) 15.2 (3 .6 ) 16.7 Effective tax rate (1.6 )% 15.2 % (1.5 )% 16.7 % (1) Represents non-taxable expense reversal due to overall decrease in allowance for accounts receivables and advance to suppliers. (2) The (1.6)% and 15.2% rate adjustments for the three months ended September 30, 2017 and 2016, and the (1.5)% and 16.7% rate adjustments for the six months ended September 30, 2017 and 2016 represent expenses primarily including stock option expenses, legal, accounting and other expenses incurred by the Company that were not deductible for PRC income tax. Jo-Jo Drugstores is incorporated in the U.S. and incurred a net operating loss for income tax purposes for the six months ended September 30, 2017 and 2016. As of September 30, 2017, the estimated net operating loss carry forwards for U.S. income tax purposes amounted to $1,503,000, which may be available to reduce future years’ taxable income. These carry forwards will expire if not utilized by 2032. Management believes that the realization of the benefits arising from this loss appears to be uncertain due to the Company’s continuing losses for U.S. income tax purposes. Accordingly, the Company has provided a 100% valuation allowance at September 30, 2017. There was no net change in the valuation allowance for the six months ended September 30, 2017 and 2016. Management reviews this valuation allowance periodically and makes adjustments as necessary. Taxes payable at September 30, 2017 and March 31, 2017 consisted of the following: September 30 March 31, VAT $ 515,358 $ 615,067 Income tax 18,494 19,416 Others 36,779 47,456 Total taxes payable $ 570,631 $ 681,939 The Company has adopted FASB ASC Topic 740-10-05, “Income Taxes.” To date, the adoption of this interpretation has not impacted the Company’s financial position, results of operations, or cash flows. The Company performed a self-assessment and the Company’s liability for income taxes includes liability for unrecognized tax benefits, interest and penalties which relate to tax years still subject to review by taxing authorities. Audit periods remain open for review until the statute of limitations has passed, which in the PRC is usually 5 years. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2017 and September 30, 2016, management considered that the Company had no uncertain tax positions affecting its consolidated financial position and results of operations or cash flows, and will continue to evaluate for any uncertain position in future. There are no estimated interest costs and penalties provided in the Company’s consolidated financial statements for the six months ended September 30, 2017 and 2016, respectively. The Company’s tax positions related to open tax years are subject to examination by the relevant tax authorities, the most significant of which is the China Tax Authority.

Postretirement Benefits

Postretirement Benefits	6 Months Ended
	Sep. 30, 2017
Postretirement Benefits [Abstract]
POSTRETIREMENT BENEFITS	Note 16 – POSTRETIREMENT BENEFITS Regulations in the PRC require the Company to contribute to a defined contribution retirement plan for all permanent employees. The contribution for each employee is based on a percentage of the employee’s current compensation as required by the local government. The Company contributed $276,490 and $222,732 in employment benefits and pension for the three months ended September 30, 2017 and 2016, respectively. The Company contributed $559,734 and $470,632 in employment benefits and pension for the six months ended September 30, 2017 and 2016, respectively.

Related Party Transactions and

Related Party Transactions and Arrangements	6 Months Ended
	Sep. 30, 2017
Related Party Transactions and Arrangements [Abstract]
RELATED PARTY TRANSACTIONS AND ARRANGEMENTS	Note 17 – RELATED PARTY TRANSACTIONS AND ARRANGEMENTS Amounts payable to related parties are summarized as follows: September 30, March 31, Due to a director and CEO (1) 755,734 927,052 (1) Due to foreign exchange restrictions, the Company’s director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. As of September 30, 2017 and March 31, 2017, notes payable totaling $3,684,220 and $3,974,193 were secured by the personal properties of certain of the Company’s shareholders, respectively. The Company leases from Mr. Lei Liu a retail space; the lease expires in September 2018. Rent expenses totaled $4,435 and $4,499 for the three months ended September 30, 2017 and 2016, respectively. Rent expenses totaled $8,870 and $9,092 for the six months ended September 30, 2017 and 2016, respectively. The amounts owed under the lease for the three months ended September 30, 2017 and 2016 were not paid to Mr. Liu as of September 30, 2017.

Warrants

Warrants	6 Months Ended
	Sep. 30, 2017
Warrants [Abstract]
WARRANTS	Note 18 – WARRANTS In connection with the registered direct offering closed on July 19, 2015, the Company issued to an investor a warrant to purchase up to 600,000 shares of common stock at an exercise price of $3.10 per share. The warrant became exercisable on January 19, 2016 and will expire on January 18, 2021. In connection with the offering, the Company also issued a warrant to its placement agent of this offering, pursuant to which the agent may purchase up to 6% of the aggregate number of shares of common stock sold in the offering, i.e. 72,000 shares. Such warrant has the same terms as the warrant issued to investor in the offering. The fair value of the warrants issued to purchase 672,000 shares as described above was estimated by using the binominal pricing model with the following assumptions: Common Stock Common Stock September 30, (1) March 31, Stock price $ 1.62 $ 1.80 Exercise price $ 3.10 $ 3.10 Annual dividend yield - % - % Expected term (years) 3.30 3.80 Risk-free interest rate 1.62 % 0.87 % Expected volatility 70.81 % 90.73 % (1) As of September 30, 2017, the warrants had not been exercised. Upon evaluation, the warrants meet the definition of a derivative under FASB ASC 815, as the Company cannot avoid a net cash settlement under certain circumstances. Accordingly, the fair value of the warrants was classified as a liability of $496,217 as of March 31, 2017. For the three and six months ended September 30, 2017, the Company recognized a gain of $148,427 and $198,751 for the investor warrant and placement agent warrant, from the change in fair value of the warrant liability, respectively. As a result, the warrant liability is carried on the consolidated balance sheets at the fair value of $297,466 for the investor warrant and placement agent warrant, collectively, as of September 30, 2017.

Stockholder's Equity

Stockholder's Equity	6 Months Ended
	Sep. 30, 2017
Stockholder's Equity [Abstract]
STOCKHOLDER'S EQUITY	Note 19 – STOCKHOLDER’S EQUITY Common stock On January 23, 2017, the Company closed a private offering with one institutional investor (the “Investor”) pursuant to which the Company sold to the Investor, and the Investor purchased from the Company, an aggregate of 4,840,000 shares of the common stock, par value $0.001 per share, of the Company, at a purchase price of $2.20 per share, for aggregate gross proceeds to the Company of $10,648,000 (the “Private Placement”). Stock-based compensation The Company accounts for share-based payment awards granted to employees and directors by recording compensation expense based on estimated fair values. The Company estimates the fair value of share-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. Share-based awards are attributed to expenses using the straight-line method over the vesting period. The Company determines the value of each option award that contains a market condition using a Monte Carlo Simulation valuation model, while all other option awards are valued using the Black-Scholes valuation model as permitted under FASB ASC 718 “Compensation - Stock Compensation.” The assumptions used in calculating the fair value of share-based payment awards represent the Company’s best estimates. The Company’s estimates of the fair values of stock options granted and the resulting amounts of share-based compensation recognized may be impacted by certain variables including stock price volatility, employee stock option exercise behaviors, additional stock option modifications, estimates of forfeitures, and the related income tax impact. On June 3, 2016, the Company granted a total of 1,630,000 shares of restricted common stock to its key employees in its retail drugstores and online pharmacy under the Company’s 2010 Equity Incentive Plan, as amended. The stock awards vests in three years from the date of the grant. The trading value of the Company’s common stock on June 3, 2016 was $1.62. For the three months ended September 30, 2017 and 2016, $221,859 and $221,859 was recorded as service compensation expense, respectively. For the six months ended September 30, 2017 and 2016, $441,306 and $286,970 was recorded as service compensation expense, respectively. Stock option On November 18, 2014, the Company granted a total of 967,000 shares of stock options under the Plan to a group of a total of 46 grantees including directors, officers and employees. The exercise price of the stock option is $2.50. The option vests on November 18, 2017, provided that the grantees are still employed by the Company on such a date. The options will be exercisable for five years from the vesting date, or November 18, 2017 until November 17, 2022. For the six months ended September 30, 2017 and 2016, $248,066 and $248,066 was recorded as compensation expense. For the three months ended September 30, 2017 and 2016, $124,033 and $124,033 was recorded as compensation expense. As of September 30, 2017, there was approximately $0.07 million of total unrecognized compensation costs related to stock option compensation arrangements granted which is expected to be recognized over the remaining weighted-average period of 0.13 years. Statutory reserves Statutory reserves represent restricted retained earnings. Based on their legal formation, the Company is required to set aside 10% of its net income as reported in their statutory accounts on an annual basis to the Statutory Surplus Reserve Fund (the “Reserve Fund”). Once the total amount set aside in the Reserve Fund reaches 50% of the entity’s registered capital, further appropriations become discretionary. The Reserve Fund can be used to increase the entity’s registered capital upon approval by relevant government authorities or eliminate its future losses under PRC GAAP upon a resolution by its board of directors. The Reserve Fund is not distributable to shareholders, as cash dividends or otherwise, except in the event of liquidation. Appropriations to the Reserve Fund are accounted for as a transfer from unrestricted earnings to statutory reserves. During the three and six months ended September 30, 2017 and 2016, the Company did not make appropriations to statutory reserves. There are no legal requirements in the PRC to fund the Reserve Fund by transfer of cash to any restricted accounts, and the Company does not do so.

(Loss) Income Per Share

(Loss) Income Per Share	6 Months Ended
	Sep. 30, 2017
(Loss) Income Per Share [Abstract]
(LOSS) INCOME PER SHARE	Note 20 – (LOSS) INCOME PER SHARE The Company reports earnings per share in accordance with the provisions of the FASB’s related accounting standard. This standard requires presentation of basic and diluted earnings per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings per share excludes dilution, but includes vested restricted stocks and is computed by dividing income available to common stockholders by the weighted average common shares outstanding during the period. Diluted earnings per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock. The following is a reconciliation of the basic and diluted (loss) earnings per share computation: Three months ended Six months ended 2017 2016 2017 2016 Net income attributable to controlling interest $ (1,168,709 ) $ 97,870 $ (2,588,013 ) $ 229,023 Weighted average shares used in basic computation 25,214,678 19,375,773 25,214,678 18,239,065 Diluted effect of purchase options and warrants - - - - Diluted effect of restricted shares - - - - Weighted average shares used in diluted computation 25,214,678 19,375,773 25,214,678 18,239,065 Income per share – Basic: Net income before noncontrolling interest $ (0.05 ) $ 0.01 $ (0.10 ) $ 0.01 Add: Net loss attributable to noncontrolling interest $ - $ - $ - $ - Net income attributable to controlling interest $ (0.05 ) $ 0.01 $ (0.10 ) $ 0.01 Loss per share – Diluted: Net income before noncontrolling interest $ (0.05 ) $ 0.01 $ (0.10 ) $ 0.01 Add: Net income attributable to noncontrolling interest $ - $ - $ - $ - Net income attributable to controlling interest $ (0.05 ) $ 0.01 $ (0.10 ) $ 0.01 For the three and six months ended September 30, 2017, 967,000 shares underlying employee stock options and 600,000 shares underlying outstanding purchase options to an investor, and 72,000 shares underlying outstanding purchase option to an investment placement agent were excluded from the calculation of diluted loss per share as the options were anti-dilutive.

Segments

Segments	6 Months Ended
	Sep. 30, 2017
Segments [Abstract]
SEGMENTS	Note 21 – SEGMENTS The Company operates within four main reportable segments: retail drugstores, online pharmacy, drug wholesale and herb farming. The retail drugstores segment sells prescription and over-the-counter (“OTC”) medicines, TCM, dietary supplements, medical devices, and sundry items to retail customers. The online pharmacy sells OTC drugs, dietary supplements, medical devices and sundry items to customers through several third-party platforms such as Alibaba’s Tmall, JD.com and Amazon.com, and the Company’s own platform all over China. The drug wholesale segment includes supplying the Company’s own retail drugstores with prescription and OTC medicines, TCM, dietary supplement, medical devices and sundry items (which sales have been eliminated as intercompany transactions), and also selling them to other drug vendors and hospitals. The Company’s herb farming segment cultivates selected herbs for sales to other drug vendors. The Company is also involved in online sales and clinic services that do not meet the quantitative thresholds for reportable segments and are included in the retail drugstores segment. The segments’ accounting policies are the same as those described in the summary of significant accounting policies. The Company evaluates performance based on profit or loss from operations before interest and income taxes not including nonrecurring gains and losses. The Company’s reportable business segments are strategic business units that offer different products and services. Each segment is managed separately because each requires different operations and markets to distinct classes of customers. The following table presents summarized information by segment of the continuing operations for the three months ended September 30, 2017. Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 15,047,615 $ 3,065,016 5,378,412 - 23,491,043 Cost of goods 10,804,453 2,665,299 4,463,694 - 17,933,446 Gross profit $ 4,243,162 $ 399,717 914,718 - 5,557,597 Selling expenses 2,582,089 459,785 1,308,898 - 4,350,772 General and administrative expenses 2,742,437 107,616 5,361 141 2,855,555 (Loss) income from operations $ (1,081,364 ) $ (167,684 ) (399,541 ) (141 ) (1,648,730 ) Depreciation and amortization $ (416,231 ) $ - 121,767 (119,461 ) (413,925 ) Total capital expenditures $ 149,568 $ - 45,451 - 195,019 * Includes accounts receivable allowance reversal of $654,606 and additional advance to suppliers allowance of $864,554. The following table presents summarized information by segment of the continuing operations for the three months ended September 30, 2016. Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 12,806,987 $ 3,783,725 $ 3,570,123 $ - $ 20,160,835 Cost of goods 9,037,377 3,386,588 3,383,863 - 15,807,828 Gross profit $ 3,769,610 $ 397,137 $ 186,260 $ - $ 4,353,007 Selling expenses 2,192,969 450,866 379,487 - 3,023,322 General and administrative expenses 1,652,375 - (276,910 )* 7,185 1,382,650 (Loss) income from operations $ (75,734 ) $ (53,729 ) $ 83,683 $ (7,185 ) $ (52,965 ) Depreciation and amortization $ 466,051 $ - $ 6,644 $ - $ 472,695 Total capital expenditures $ 40,084 $ - $ - $ - $ 40,084 * Includes accounts receivable and advance to suppliers allowance reversal of $318,789. The following table presents summarized information of the continuing operation by segment for the six months ended September 30, 2017: Retail Online Drug Herb Total Revenue $ 28,067,985 $ 6,200,705 10,892,721 45,161,411 Cost of goods 20,540,661 5,509,797 9,375,695 35,426,153 Gross profit $ 7,527,324 $ 690,908 1,517,026 9,735,258 Selling expenses 5,001,645 975,172 2,290,814 8,267,631 General and administrative expenses 4,012,213 177,905 380,833 10,047 4,580,998 (Loss) income from operations $ (1,486,534 ) $ (462,169 ) (1,154,621 ) (10,047 ) (3,113,371 ) Depreciation and amortization $ (329,242 ) $ - 204,374 (124,868 ) Total capital expenditures $ 206,142 $ - 6,216 212,358 * Includes accounts receivable and advance to suppliers allowance reversal of $280,645. The following table presents summarized information of the continuing operation by segment for the six months ended September 30, 2016: Retail Online Drug Herb Total Revenue $ 25,515,229 $ 8,854,804 $ 6,726,717 $ - $ 41,096,750 Cost of goods 18,124,144 7,800,678 6,337,117 - 32,261,939 Gross profit $ 7,391,085 $ 1,054,126 $ 389,600 $ - $ 8,834,811 Selling expenses 4,401,929 912,912 391,202 - 5,706,043 General and administrative expenses 3,180,948 - 108,476 11,708 3,301,132 (Loss) income from operations $ (191,792 ) $ 141,214 $ (110,078 ) $ (11,708 ) $ (172,364 ) Depreciation and amortization $ 412,859 $ - $ 53,711 $ - $ 466,570 Total capital expenditures $ 49,298 $ - $ - $ - $ 49,298 * Includes accounts receivable and advance to suppliers allowance reversal of $280,645. The Company does not have long-lived assets located outside the PRC. In accordance with the enterprise-wide disclosure requirements of FASB’s accounting standard, the Company’s net revenue from external customers through its retail drugstores by main product category for the is as follows: Three months ended Six months ended 2017 2016 2017 2016 Prescription drugs $ 4,891,435 $ 4,097,127 $ 9,486,789 $ 8,368,229 Over-the-counter drugs 6,780,715 5,188,201 12,424,677 10,063,556 Nutritional supplements 1,638,031 965,346 2,675,363 2,142,086 Traditional Chinese medicine 938,688 1,120,808 1,951,199 2,049,831 Sundry products 362,443 223,799 624,479 478,357 Medical devices 436,303 1,176,034 905,478 2,377,497 Total $ 15,047,615 $ 12,771,315 $ 28,067,985 $ 25,479,556 The Company’s net revenue from external customers through online pharmacy by main products is as follows: Three months ended Six months ended 2017 2016 2017 2016 Prescription drugs $ - $ - $ - $ - Over-the-counter drugs 1,385,899 1,309,143 2,503,291 2,946,434 Nutritional supplements 334,806 536,456 850,882 1,444,479 Traditional Chinese medicine 10,182 - 10,182 - Sundry products 422,388 405,341 841,421 1,071,504 Medical devices 911,741 1,532,784 1,994,929 3,392,386 Total $ 3,065,016 $ 3,783,724 $ 6,200,705 $ 8,854,803 The Company’s net revenue from external customers through wholesale by main products is as follows: Three months ended Six months ended 2017 2016 2017 2016 Prescription drugs $ 3,077,232 $ 1,948,879 $ 6,474,633 $ 3,846,484 Over-the-counter drugs 2,248,503 1,621,129 4,349,153 2,840,030 Nutritional supplements 12,279 31,170 28,537 70,493 Traditional Chinese medicine 604 4,453 604 4,453 Sundry products - - - - Medical devices 39,794 165 39,794 931 Total $ 5,378,412 $ 3,605,796 $ 10,892,721 $ 6,762,391

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Sep. 30, 2017
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	Note 22 – COMMITMENTS AND CONTINGENCIES Operating lease commitments The Company recognizes lease expenses on a straight line basis over the term of its leases in accordance with the relevant accounting standards. The Company has entered into various tenancy agreements for its store premises and for the land leased from a local government to farm herbs. The Company’s commitments for minimum rental payments under its leases for the next five years and thereafter are as follows: Periods ending September 30, Retail Online Drug Herb Total 2018 $ 3,875,101 $ 36,366 $ 72,732 $ - $ 3,984,199 2019 3,462,529 36,366 72,732 - 3,571,627 2020 2,704,078 36,366 72,732 - 2,813,176 2021 2,156,248 12,122 24,244 - 2,192,614 2022 1,653,163 - - - 1,653,163 Thereafter 2,556,744 - - - 2,556,744 Total rent expense amounted to $1,076,749 and $722,190 for the three months ended September 30, 2017 and 2016, respectively.

Subsequent Events

Subsequent Events	6 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 23 – SUBSEQUENT EVENTS Based on a joint venture agreement (the “JV”) with CareRetail (HK) Holdings Limited (“CareRetail HK”) entered into on January 18, 2017, Jiuzhou Pharmacy will set up a JV with CareRetail HK. The JV is intended to be an investment vehicle in acquiring or cooperating with another pharmaceutical chain in China. As certain important terms (such as the amount of capital) require further discussion, as of the date hereof, the JV has not been set up.

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2017
Summary of Significant Accounting Policies [Abstract]
Basis of presentation and consolidation	Basis of presentation and consolidation The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries and VIEs. All significant inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation.
Consolidation of variable interest entities	Consolidation of variable interest entities In accordance with accounting standards regarding consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary is required to consolidate the VIE for financial reporting purposes. The Company has concluded, based on the contractual arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each a VIE and that the Company’s wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual returns. Additionally, as Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service are under common control, the consolidated financial statements have been prepared as if the transactions had occurred retroactively as to the beginning of the reporting period of these consolidated financial statements. Control and common control are defined under the accounting standards as “an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership interest of each entity.” Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized in the voting rights agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly, the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin Management, in turn, is owned by Renovation, which is owned by the Company.
Risks and Uncertainties	Risks and Uncertainties The operations of the Company are located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s operations in the PRC are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results. The Company has significant cash deposits with suppliers in order to obtain and maintain inventory. The Company’s ability to obtain products and maintain inventory at existing and new locations is dependent upon its ability to post and maintain significant cash deposits with its suppliers. In the PRC, many vendors are unwilling to extend credit terms for product sales that require cash deposits to be made. The Company does not generally receive interest on any of its supplier deposits, and such deposits are subject to loss as a result of the creditworthiness or bankruptcy of the party who holds such funds, as well as the risk from illegal acts such as conversion, fraud, theft or dishonesty associated with the third party. If these circumstances were to arise, the Company would find it difficult or impossible, due to the unpredictability of legal proceedings in China, to recover all or a portion of the amount on deposit with its suppliers. Members of the current management team own controlling interests in the Company and are also the Owners of the VIEs in the PRC. The Company only controls the VIEs through contractual arrangements which obligate it to absorb the risk of loss and to receive the residual expected returns. As such, the controlling shareholders of the Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the Company would not retain control of the VIEs.
Use of estimates	Use of estimates The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The significant estimates made in the preparation of the accompanying unaudited condensed consolidated financial statements relate to the assessment of the carrying values of accounts receivable, advances to suppliers and related allowance for doubtful accounts, useful lives of property and equipment, inventory reserve and fair value of its purchase option derivative liability. Because of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates.
Fair value measurements	Fair value measurements The Company has adopted FASB ASC Topic 820, “Fair Value Measurement and Disclosure,” which defines fair value, establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. It does not require any new fair value measurements, but provides guidance on how to measure fair value by providing a fair value hierarchy used to classify the source of the information. It establishes a three-level valuation hierarchy of valuation techniques based on observable and unobservable inputs, which may be used to measure fair value and include the following: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Classification within the hierarchy is determined based on the lowest level of input that is significant to the fair value measurement. The Company’s financial assets and liabilities, which include financial instruments as defined by FASB ASC 820, include cash and cash equivalents, accounts receivable, accounts payable, long-term debt and derivatives. The carrying amounts of cash and cash equivalents, financial assets available for sales, accounts receivable, notes receivables, and accounts payable are a reasonable approximation of fair value due to the short maturities of these instruments (Level 1). The carrying amount of notes payable approximates fair value based on borrowing rates of similar bank loan currently available to the Company (Level 2) (See Note 13). The carrying amount of the Company’s derivative instruments is recorded at fair value and is determined based on observable inputs that are corroborated by market data (Level 2). As of September 30, 2017, the fair values of our derivative instruments that were carried at fair value (See Note 17). Active Market Observable Unobservable Total Cash and cash equivalents 16,837,873 - $ - 16,837,873 Notes payable - 12,872,045 - 12,872,045 Warrants liability - 297,466 $ - 297,466 Total 16,837,873 13,169,511 $ - 30,007,384
Revenue recognition	Revenue recognition Revenue from sales of prescription medicine at drugstores is recognized when the prescription is filled and the customer picks up and pays for the prescription. Revenue from sales of other merchandise at drugstores is recognized at the point of sale, which is when a customer pays for and receives the merchandise. Usually the majority of our merchandise, such as prescription and OTC drugs, are not allowed to be returned after the customers leave the counter. Return of other products, such as sundry products, are minimal. Sales of drugs reimbursed by the local government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. Based on historical experience, a reserve for potential loss from denial of reimbursement on certain unqualified drugs is made to the receivables from the government agency. Revenue from medical services is recognized after the service has been rendered to a customer. Revenue from online pharmacy sales is recognized when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer’s location. Any loss caused in a shipment will be reimbursed by the Company’s courier company. Our sales policy allows for the return of certain merchandises without reason within seven days after customer’s receipt of the applicable merchandise. A proper sales reserve is made to account for the potential loss from returns from customers. Historically, sales returns seven days after merchandise receipts have been minimal. Revenue from sales of merchandise to non-retail customers is recognized when the following conditions are met: (1) persuasive evidence of an arrangement exists (sales agreements and customer purchase orders are used to determine the existence of an arrangement); (2) delivery of goods has occurred and risks and benefits of ownership have been transferred, which is when the goods are received by the customer at its designated location in accordance with the sales terms; (3) the sales price is fixed or determinable; and (4) collectability is probable. Historically, sales returns have been minimal. The Company’s revenue is net of value added tax (“VAT”) collected on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities. In March 2016, the FASB issued ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Gross versus Net),” clarifying the principal versus agent guidance in the new revenue recognition standard, by revising the indicators to focus on evidence that the Company is a principal. In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” reducing the complexity when applying the guidance for identifying performance obligations and clarifying how to determine whether revenue related to a performance obligation for an intellectual property license is recognized over time or at a point in time. In May 2016, the FASB issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients,” clarifying certain core recognition principles including collectability, sales tax presentation, noncash consideration, contract modifications and completed contracts at transition. These ASUs are effective for the Company beginning in the first quarter of the fiscal year of 2019, allow for early adoption in the first quarter of 2017 and may be applied using either a full retrospective approach or a modified retrospective approach. The Company is planning to adopt the new accounting standard ASC 606 and all related amendment using a modified retrospective approach. Revenue from sales at drugstores continues to be recognized at the point of sale, which is when a customer pays for and receives the merchandise. Revenue from online pharmacy sales is recognized when merchandise is shipped to customers. Revenue from sales of merchandise to non-retail customers is recognized upon delivery of goods. The Company does not expect the adoption of the New Revenue Standard to have material impact on its net income on an ongoing basis. Its interpretation is subject to change as a result of future change in market conditions or product offering.
Restricted cash	Restricted cash The Company’s restricted cash consists of cash and long-term deposits in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset.
Accounts receivable	Accounts receivable Accounts receivable represents the following: (1) amounts due from banks relating to retail sales that are paid or settled by the customers’ debit or credit cards, (2) amounts due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine, and medical services that are paid or settled by the customers’ medical insurance cards, (3) amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce platforms and (4) amounts due from non-retail customers for sales of merchandise. Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as necessary. In the Company’s retail business, accounts receivable mainly consist of reimbursements due from the government insurance bureaus and commercial health insurance programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which it determines to be uncollectible after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated reserves on related outstanding accounts receivable based on historical trends. In the Company’s online pharmacy business, accounts receivable primarily consist of amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce platforms. To purchase pharmaceutical products from an e-commerce platforms such as Tmall, customers are required to submit payment to certain non-bank third party payment instruments, such as Alipay, which, in turn, reimburse the Company within seven days to a month. Except for customer returns of sold products, the receivables from these payments instruments are rarely uncollectible. In its wholesale business, the Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, bad debt percentages are determined by management, based on historical experience and the current economic climate, are applied to customers’ balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate.
Advances to suppliers	Advances to suppliers Advances to suppliers consist of prepayments to our vendors, such as pharmaceutical manufacturers and other distributors. Since the acquisition of Jiuxin Medicine, we have transferred almost all logistics services of our retail drugstores to Jiuxin Medicine. Jiuzhou Pharmacy only directly purchases certain non-medical products, such as certain nutritional supplements. As a result, almost all advances to suppliers are made by Jiuxin Medicine. Advances to suppliers for our drug wholesale business consist of prepayments to our vendors, such as pharmaceutical manufacturers and other distributors. We typically receive products from vendors within three to nine months after making prepayments. We continuously monitor delivery from, and payments to, our vendors while maintaining a provision for estimated credit losses based upon historical experience and any specific supplier issues, such as discontinuing of inventory supply, that have been identified. If we have difficulty receiving products from a vendor, we take the following steps: cease purchasing products from such vendor, ask for return of our prepayment promptly, and if necessary, take legal action. If all of these steps are unsuccessful, management then determines whether the prepayments should be reserved or written off.
Inventories	Inventories Inventories are stated at the lower of cost or market value. Cost is determined using the first in first out (FIFO) method. Market value is the lower of replacement cost or net realizable value. The Company carries out physical inventory counts on a monthly basis at each store and warehouse location. Herbs that the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development cost. All costs are accumulated until the time of harvest and then allocated to harvested herbs costs when the herbs are sold. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses and damaged merchandise that are identified. The Company provides a reserve for estimated inventory obsolescence or excess quantities on hand equal to the difference, if any, between the cost of the inventory and its estimated realizable value.
Farmland assets	Farmland assets Herbs that the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, and labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development costs. Since April 2014, amortization of farmland development costs has been expensed instead of allocated into inventory due to unpredictable future market value of planted gingko trees. All related costs described in the above are accumulated until the time of harvest and then allocated to harvested herbs when they are sold.
Property and equipment	Property and equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets, taking into consideration the assets’ estimated residual value. Leasehold improvements are amortized over the shorter of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company’s property and equipment: Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years Maintenance, repairs and minor renewals are charged to expenses as incurred. Major additions and betterment to property and equipment are capitalized.
Intangible assets	Intangible assets Intangible assets are acquired individually or as part of a group of assets, and are initially recorded at their fair value. The cost of a group of assets acquired in a transaction is allocated to the individual assets based on their relative fair values. The estimated useful lives of the Company’s intangible assets are as follows: Estimated Land use rights 50 years Software 3 years The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets might be impaired.
Impairment of long lived assets	Impairment of long lived assets The Company evaluates long lived tangible and intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. Recoverability is measured by comparing the assets’ net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss. There were no fixed assets and farmland assets impaired for the three months ended September 30, 2017.
Notes payable	Notes payable During the normal course of business, the Company regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short maturity period of six to nine months.
Income taxes	Income taxes The Company follows FASB ASC Topic 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company has adopted FASB ASC Topic 740-10-25, which provides criteria for the recognition, measurement, presentation and disclosure of uncertain tax position. The Company must recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. The Company performed a self-assessment and the Company’s liability for income taxes includes liability for unrecognized tax benefits, interest and penalties which relate to tax years still subject to review by taxing authorities. Audit periods remain open for review until the statute of limitations has passed, which in the PRC is usually 5 years. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2017 and March 31, 2017, the management of the Company considered that the Company had no additional liabilities for uncertain tax positions affecting its consolidated financial position and results of operations or cash flows, and will continue to evaluate for any uncertain position in the future. There are no estimated interest costs and penalties provided in the Company’s consolidated financial statements for the three months ended September 30, 2017 and 2016, respectively. The Company’s tax positions related to open tax years are subject to examination by the relevant tax authorities, the most significant of which is the China Tax Authority.
Value added tax	Value added tax Sales revenue represents the invoiced value of goods, net of VAT. All of the Company’s products are sold in the PRC and are subject to a VAT on the gross sales price. The VAT rates range up to 17%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable net of payments in the accompanying financial statements. The accounting standards clarify the accounting and disclosure requirements for uncertain tax positions and prescribe a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. The accounting standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. No significant penalties, uncertain tax provisions or interest relating to income taxes were incurred during the periods ended September 30, 2017 and 2016.
Stock based compensation	Stock based compensation The Company follows the provisions of FASB ASC 718, “Compensation — Stock Compensation,” which establishes accounting standards for non-employee and employee stock-based awards. Under the provisions of FASB ASC 718, the fair value of stock issued is used to measure the fair value of services received as the Company believes such approach is a more reliable method of measuring the fair value of the services. For non-employee stock-based awards, fair value is measured based on the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is calculated and then recognized as compensation expense over the requisite performance period. For employee stock-based awards, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense with graded vesting on a straight–line basis over the requisite service period for the entire award.
Advertising and promotion costs	Advertising and promotion costs Advertising and promotion costs are expensed as incurred and amounted to $180,639 and $113,638 for the three months ended September 30, 2017 and 2016, respectively, and $320,734 and $182,487 for the six months ended September 30, 2017 and 2016, respectively. Such costs consist primarily of print and promotional materials such as flyers to local communities.
Operating leases	Operating leases The Company leases premises for retail drugstores, offices and wholesale warehouse under non-cancellable operating leases. Operating lease payments are expensed over the term of lease. A majority of the Company’s retail drugstore leases have a 3 to 10 year term with a renewal option upon the expiration of the lease; the wholesale warehouse lease has a 10-year term with a renewal option upon the expiration of the lease. The Company has historically been able to renew a majority of its drugstores leases. Under the terms of the lease agreements, the Company has no legal or contractual asset retirement obligations at the end of the lease. In addition, land leased from the government is amortized on a straight-line basis over a 30-year term.
Foreign currency translation	Foreign currency translation The Company uses the United States dollar (“U.S. dollars” or “USD”) for financial reporting purposes. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency the Renminbi (“RMB”), the currency of the PRC. In general, for consolidation purposes, the Company translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income. The balance sheet amounts, with the exception of equity, at September 30, 2017 and at March 31, 2017 were translated at 1 RMB to 0.1503 USD and at 1 RMB to 0.1451 USD, respectively. The average translation rates applied to income and cash flow statement amounts for the six months ended September 30, 2017 and 2016 were at at 1 RMB to 0.1478 USD and 1 RMB to 0.1515 USD, respectively.
Concentrations and credit risk	Concentrations and credit risk Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash and restricted cash. The Company has cash balances at financial institutions located in Hong Kong and PRC. Balances at financial institutions in Hong Kong may, from time to time, exceed Hong Kong Deposit Protection Board’s insured limits. Since March 31, 2015, balances at financial institutions and state-owned banks within the PRC are covered by insurance up to RMB 500,000 (USD 77,150) per bank. As of September 30, 2017 and March 31, 2017, the Company had deposits totaling $26,709,868 and $27,357,785 that were covered by such limited insurance, respectively. Any balance over RMB 500,000 (USD 75,150) per bank in PRC will not be covered. To date, the Company has not experienced any losses in such accounts. For the three months ended September 30, 2017, three largest vendors accounted for 61.3% of the Company’s total purchases and one vendor accounted for 16.8% of the Company’s total advances to suppliers. For the three months ended September 30, 2016, one largest vendor accounted for 30.7% of the Company’s total purchases and one vendor accounted for 9.9% of the Company’s total advances to suppliers. For the six months ended September 30, 2017, two largest vendors accounted for 39.6% of the Company’s total purchases and one vendor accounted for 16.8% of the Company’s total advances to suppliers. For the six months ended September 30, 2016, two largest vendors accounted for 38.6% of the Company’s total purchases and one vendor accounted for 9.9% of the Company’s total advances to suppliers. For the three months and six months ended September 30, 2017 and September 30, 2016, no customer accounted for more than 10% of the Company’s total sales or accounts receivable.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, “Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which removes Step 2 from the goodwill impairment test. An entity will apply a one-step quantitative test and record the amount of goodwill impairment as the excess of a reporting unit’s carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The new guidance does not amend the optional qualitative assessment of goodwill impairment. Public business entity that is a U.S. Securities and Exchange Commission filer should adopt the amendments in this ASU for its annual or any interim goodwill impairment test in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact of the adoption of ASU 2017-04 on our consolidated financial statements.

Description of Business and O30

Description of Business and Organization (Tables)	6 Months Ended
	Sep. 30, 2017
Description of Business and Organization [Abstract]
Summary of subsidiaries	Entity Name Date Established Hangzhou Jiuben Pharmacy Co., Ltd (“Jiuben Pharmacy”) April 27, 2017 Hangzhou Jiuli Pharmacy Co., Ltd (“Jiuli Pharmacy”) May 22, 2017 Hangzhou Jiuxiang Pharmacy Co., Ltd (“Jiuxiang Pharmacy”) May 26, 2017 Hangzhou Jiuheng Pharmacy Co., Ltd (“Jiuheng Pharmacy”) June 6, 2017 Hangzhou Jiujiu Pharmacy Co., Ltd (“Jiujiu Pharmacy”) June 8, 2017 Hangzhou Jiuyi Pharmacy Co., Ltd (“Jiuyi Pharmacy”) June 8, 2017 Hangzhou Jiuyuan Pharmacy Co., Ltd (“Jiuyuan Pharmacy”) July 13, 2017 Hangzhou Jiumu Pharmacy Co., Ltd (“Jiumu Pharmacy”) July 21, 2017 Hangzhou Jiurui Pharmacy Co., Ltd (“Jiurui Pharmacy”) August 4, 2017
Schedule of consolidated financial statements activities	Entity Name Background Ownership Renovation ● Incorporated in Hong Kong SAR on September 2, 2008 100% Jiuxin Management ● Established in the PRC on October 14, 2008 100% ● Deemed a wholly foreign owned enterprise (“WFOE”) under PRC law ● Registered capital of $14.5 million fully paid Shouantang Technology ● Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million 100% ● Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid ● Deemed a WFOE under PRC law ● Invests and finances the working capital of Quannuo Technology Qianhong Agriculture ● Established in the PRC on August 10, 2010 by Jiuxin Management 100% ● Registered capital of RMB 10 million fully paid ● Carries out herb farming business Jiuzhou Pharmacy (1) ● Established in the PRC on September 9, 2003 VIE by contractual arrangements (2) ● Registered capital of RMB 5 million fully paid ● Operates the “Jiuzhou Grand Pharmacy” stores in Hangzhou Jiuzhou Clinic (1) ● Established in the PRC as a general partnership on October 10, 2003 VIE by contractual arrangements (2) ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores Jiuzhou Service (1) ● Established in the PRC on November 2, 2005 VIE by contractual arrangements (2) ● Registered capital of RMB 500,000 fully paid ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores Jiuxin Medicine ● Established in PRC on December 31, 2003 VIE by contractual arrangements ● Acquired by Jiuzhou Pharmacy in August 2011 as a wholly-owned subsidiary of ● Registered capital of RMB 10 million fully paid Jiuzhou Pharmacy (2) ● Carries out pharmaceutical distribution services Jiutong Medical ● Established in the PRC on December 20, 2011 by Renovation 100% ● Registered capital of $2.6 million fully paid ● Currently has no operation Entity Name Background Ownership Shouantang Bio ● Established in the PRC in October, 2014 by Shouantang Technology 100% ● 100% held by Shouantang Technology ● Registered capital of RMB 1,000,000 fully paid ● Sells nutritional supplements under its own brand name Jiuyi Technology ● Established in the PRC on September 10, 2015 100% ● 100% held by Renovation ● Registered capital of USD 5,000,000 (USD 2,500,000 paid) ● Technical support to online pharmacy Kahamadi Bio ● Established in the PRC in May 2016 49% ● 49% held by Shouantang Bio ● Registered capital of RMB 10 million ● Develop brand name for nutritional supplements Lin’An Jiuzhou ● Established in the PRC in March 31, 2017 100% ● 100% held by Jiuxin Management ● Registered capital of RMB 5 million (RMB 550,000 paid) ● Explore retail pharmacy market in Lin’An City Jiuben Pharmacy ● Established in the PRC in April 27, 2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City Jiumu Pharmacy ● Established in the PRC in July 21, 2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City Jiuheng Pharmacy ● Established in the PRC in June 6, 2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City Jiujiu Pharmacy ● Established in the PRC in June 8, 2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City Jiuli Pharmacy ● Established in the PRC in May 22 ,2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City Jiurui Pharmacy ● Established in the PRC in August 4, 2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City JiuxiangPharmacy ● Established in the PRC in May 26, 2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City Entity Name Background Ownership Jiuyi Pharmacy ● Established in the PRC in June 8, 2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City Jiuyuan Pharmacy ● Established in the PRC in July 13, 2017 VIE by contractual arrangements as ● 100% held by Jiuzhou Pharmacy a wholly-owned subsidiary of ● Registered capital of RMB 100,000 Jiuzhou Pharmacy (2) ● Operates a retail pharmacy drugstore in Hangzhou City (1) Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service have been under the common control of Mr. Lei Liu, Mr. Chong’an Jin and Ms. Li Qi, the three shareholders of Renovation (the “Owners”) since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting rights agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company’s respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy. (2) To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity (“VIE”) under the accounting standards of the Financial Accounting Standards Board (“FASB”). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiary under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company.

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Sep. 30, 2017
Summary of Significant Accounting Policies [Abstract]
Summary of fair values of derivative instruments	Active Market Observable Unobservable Total Cash and cash equivalents 16,837,873 - $ - 16,837,873 Notes payable - 12,872,045 - 12,872,045 Warrants liability - 297,466 $ - 297,466 Total 16,837,873 13,169,511 $ - 30,007,384
Schedule of estimated useful lives of property and equipment	Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years
Schedule of estimated useful lives of intangible assets	Estimated Land use rights 50 years Software 3 years

Trade Accounts Receivable (Tabl

Trade Accounts Receivable (Tables)	6 Months Ended
	Sep. 30, 2017
Trade Accounts Receivable/Other Receivable [Abstract]
Schedule of trade accounts receivable	September 30, March 31, Accounts receivable $ 12,270,651 $ 9,977,101 Less: allowance for doubtful accounts (2,070,109 ) (1,415,505 ) Trade accounts receivable, net $ 10,200,542 $ 8,561,596

Other Receivable (Tables)

Other Receivable (Tables)	6 Months Ended
	Sep. 30, 2017
Trade Accounts Receivable/Other Receivable [Abstract]
Schedule of other receivable	September 30, March 31, Deposit* $ 1,216,800 $ 855,755 Advance to employees 584,996 652,436 Accrued supplier rebate** 190,554 321,993 Interest receivable*** 240,410 Others 418,825 465,593 Less: allowance for doubtful accounts (27,526 ) (26,584 ) Other receivable, net $ 2,624,059 $ 2,269,193 * It refers to various advances deposits made to service providers and commercial platforms such as Alibaba’s Tmall, in order to carry business via these service providers and platforms. ** It refers to supplier rebate receivables, which are computed based on our sales volume of the suppliers’ products. *** It refers to accrued interest receivable from several three-year bank deposits, which are used as a pledge for bank-guranteed notes payable (see Note 14).

Other Current Assets (Tables)

Other Current Assets (Tables)	6 Months Ended
	Sep. 30, 2017
Other Current Assets [Abstract]
Schedule of other current assets	September 30 March 31, Prepaid rental expenses (1) $ 1,395,985 $ 1,171,472 Prepaid and other current assets 408,669 394,683 Total $ 1,804,654 $ 1,566,155 (1) Represents store and office rental expenses that were usually prepaid and amortized over the prepayment period. The increase reflects additional prepaid rental for new stores.

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Sep. 30, 2017
Property and Equipment [Abstract]
Schedule of property and equipment	September 30, March 31, Building $ 1,611,055 $ 1,555,923 Leasehold improvements 12,229,600 11,783,611 Farmland development cost 1,796,971 1,735,475 Office equipment and furniture 5,126,811 5,339,005 Motor vehicles 475,446 585,769 Total 21,239,883 20,999,783 Less: Accumulated depreciation (14,861,284 ) (14,489,479 ) Impairment* (2,365,317 ) (2,247,147 ) Construction-in-progress** 520,108 - Property and equipment, net $ 4,533,390 $ 4,263,157 * The variance of impairment from March 31, 2017 to September 30, 2017 is solely caused by exchange rate variance. ** Includes clinic renovation expense of $70,798 and SAP (a popular ERP software) implementation fee of $449,309. The clinic renovation has been completed at the end of October 2017. SAP system is expected to be implemented by the end of 2017.

Advances to Suppliers (Tables)

Advances to Suppliers (Tables)	6 Months Ended
	Sep. 30, 2017
Advances to Suppliers [Abstract]
Schedule of advance to suppliers	September 30, March 31, Advance to suppliers $ 6,280,908 $ 7,006,396 Less: allowance for doubtful accounts (2,366,809 ) (1,502,255 ) Advance to suppliers, net $ 3,914,099 $ 5,504,141 * In order to collect a larger rebate for certain merchandise, such as Colla corii asini

Farmland Assets (Tables)

Farmland Assets (Tables)	6 Months Ended
	Sep. 30, 2017
Farmland Assets [Abstract]
Schedule of farmland assets	September 30, March 31, 2017 2017 Farmland assets $ 2,273,593 $ 2,195,787 Less: Impairment* (1,529,337 ) (1,477,000 ) Farmland assets, net $ 744,256 $ 718,787 * The estimated fair value is estimated to be lower than its investment value as of September 30, 2017 and March 31, 2017.

Other Noncurrent Assets (Tables

Other Noncurrent Assets (Tables)	6 Months Ended
	Sep. 30, 2017
Other Noncurrent Assets [Abstract]
Schedule of other noncurrent assets	September 30, March 31, Forest land use rights* $ 1,192,217 $ 1,177,005 Long-term prepaid store rent (over one year)** 135,230 - Total $ 1,327,447 $ 1,177,005 * The prepayment for lease of forest land use rights is a payment made to a local government in connection with entering into an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060. ** In order to secure better terms in a lease agreement, the Company agreed to pay two-year rent at the beginning of the lease.
Schedule of amortizations of the prepayment for lease of land use right	For the year ending September 30, Amount 2018 $ 28,233 2019 28,233 2020 28,233 2021 28,233 2022 28,233 Thereafter 1,057,869

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Sep. 30, 2017
Intangible Assets [Abstract]
Schedule of net intangible assets	September 30, March 31, License (1) $ 1,747,477 $ 1,394,546 Land use rights (2) 1,465,229 1,415,086 Total intangible assets 3,212,706 2,809,632 Less: accumulated amortization (115,160 ) (97,021 ) Intangible assets, net $ 3,097,546 $ 2,712,611 (1) This represents the fair value of the licenses of insurance applicable drugstores acquired from Sanhao Pharmacy, a drugstore chain Jiuzhou Pharmacy acquired in 2014. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. The owners of these acquried drugstores agreed to cease their stores’ business and liquidate all of the stores’ accounts before Jiuzhou Pharmacy acquired their stores. As a result, Jiuzhou Pharmacy has not obtained any assets or liabilities from the stores, but was able to transfer the Certificate to our new store opened at the same time. (2) In July 2013, the Company purchased the land use rights of a plot of farmland in Lin’an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as our farming business in Lin’an has not grown, the Company does not expect completion of the plant in the near future.

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Sep. 30, 2017
Notes Payable [Abstract]
Schedule of credit facilities with bank	Origination Maturity September 30, March 31, Beneficiary Endorser date date 2017 2017 Jiuzhou Pharmacy (1) HUB 10/09/16 04/09/17 - 1,755,879 Jiuzhou Pharmacy (1) HUB 10/09/16 04/09/17 - 341,676 Jiuzhou Pharmacy (1) HUB 11/08/16 05/08/17 - 1,637,419 Jiuzhou Pharmacy (1) HUB 11/11/16 05/11/17 - 314,897 Jiuzhou Pharmacy (1) HUB 12/05/16 06/05/17 - 1,508,042 Jiuzhou Pharmacy (1) HUB 12/29/16 06/29/17 - 1,205,419 Jiuzhou Pharmacy (1) HUB 12/29/16 06/29/17 - 1,030,309 Jiuzhou Pharmacy (2) ZTCB 12/27/16 06/27/17 - 580,456 Jiuzhou Pharmacy (1) HUB 02/06/17 08/06/17 - 2,253,804 Jiuzhou Pharmacy (1) HUB 03/07/17 09/07/17 - 117,542 Jiuzhou Pharmacy (1) HUB 03/07/17 09/07/17 - 267,651 Jiuzhou Pharmacy (1) HUB 03/07/17 09/07/17 - 1,678,481 Jiuzhou Pharmacy (1) HUB 04/05/17 10/05/17 1,345,036 - Jiuzhou Pharmacy (1) HUB 05/04/17 11/04/17 1,806,808 - Jiuzhou Pharmacy (1) HUB 06/05/17 12/05/17 1,561,478 - Jiuzhou Pharmacy (1) HUB 06/05/17 12/05/17 354,534 - Jiuzhou Pharmacy (1) HUB 06/29/17 12/29/17 1,074,330 - Jiuzhou Pharmacy (1) HUB 06/29/17 12/29/17 826,408 - Jiuzhou Pharmacy (1) HUB 06/29/17 12/29/17 1,984,650 - Jiuzhou Pharmacy (1) HUB 08/09/17 02/09/18 1,357,600 - Jiuzhou Pharmacy (1) HUB 09/05/17 12/05/17 267,756 - Jiuzhou Pharmacy (1) HUB 09/05/17 03/05/18 2,293,445 - Total $ 12,872,045 $ 12,691,575 (1) As of March 31, 2017, the Company had $12,111,119 (RMB 81,459,343.5) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $1,328,098 (RMB 9,152,104.2) with HUB as collateral against these bank notes. As of September 30, 2017, the Company had $12,872,045 (RMB 85667428.6) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $1,432,935 (RMB 9,536,623) with HUB as collateral against these bank notes. Additionally, a total of $8,785,866 deposit (RMB 58,472,647.3) , which matures in three years, was deposited into HUB as a collateral for current and future notes payable from HUB. (2) As of March 31, 2017, the Company had $580,456 (RMB 4,000,000) of notes payable from ZTCB, with restricted cash in the amount of $290,228 (RMB 2,000,000) held at the bank. As of September 30, 2017, the Company had no notes payable from ZTCB.

Taxes (Tables)

Taxes (Tables)	6 Months Ended
	Sep. 30, 2017
Taxes [Abstract]
Schedule of income tax provisions	Three months ended Six months ended 2017 2016 2017 2016 Income tax $ 18,047 $ 17,484 $ 38,585 $ 45,918
Schedule of income arising in or derived from tax jurisdiction which each entity domiciled	Entity Income Tax Jurisdiction Jo-Jo Drugstores United States Renovation Hong Kong, PRC All other entities Mainland, PRC
Schedule of reconciliation of the U.S. statutory tax rates with Company's effective tax rate	For the three months ended For the six months ended September 30, September 30, 2017 2016 2017 2016 U.S. Statutory rates 34 .0% 34 .0 % 34.0 % 34.0 % Foreign income not recognized in the U.S. (34.0 ) (34.0 ) (34.0 ) (34.0 ) China income taxes 25.0 25.0 25.0 25.0 Change in valuation allowance (1) (18 .4 ) (25.0 ) (2 2.9 ) (25.0 ) Non-deductible expenses-permanent difference (2) (8 .2 ) 15.2 (3 .6 ) 16.7 Effective tax rate (1.6 )% 15.2 % (1.5 )% 16.7 % (1) Represents non-taxable expense reversal due to overall decrease in allowance for accounts receivables and advance to suppliers. (2) The (1.6)% and 15.2% rate adjustments for the three months ended September 30, 2017 and 2016, and the (1.5)% and 16.7% rate adjustments for the six months ended September 30, 2017 and 2016 represent expenses primarily including stock option expenses, legal, accounting and other expenses incurred by the Company that were not deductible for PRC income tax.
Schedule of taxes payable	September 30 March 31, VAT $ 515,358 $ 615,067 Income tax 18,494 19,416 Others 36,779 47,456 Total taxes payable $ 570,631 $ 681,939

Related Party Transactions an42

Related Party Transactions and Arrangements (Tables)	6 Months Ended
	Sep. 30, 2017
Related Party Transactions and Arrangements [Abstract]
Schedule of amounts payable to related parties	September 30, March 31, Due to a director and CEO (1) 755,734 927,052 (1) Due to foreign exchange restrictions, the Company’s director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States.

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Sep. 30, 2017
Warrants [Abstract]
Schedule of estimated fair value of warrants using the binominal pricing model	Common Stock Common Stock September 30, (1) March 31, Stock price $ 1.62 $ 1.80 Exercise price $ 3.10 $ 3.10 Annual dividend yield - % - % Expected term (years) 3.30 3.80 Risk-free interest rate 1.62 % 0.87 % Expected volatility 70.81 % 90.73 % (1) As of September 30, 2017, the warrants had not been exercised.

(Loss) Income Per Share (Tables

(Loss) Income Per Share (Tables)	6 Months Ended
	Sep. 30, 2017
(Loss) Income Per Share [Abstract]
Schedule of reconciliation of basic and diluted (loss) earnings per share computation	Three months ended Six months ended 2017 2016 2017 2016 Net income attributable to controlling interest $ (1,168,709 ) $ 97,870 $ (2,588,013 ) $ 229,023 Weighted average shares used in basic computation 25,214,678 19,375,773 25,214,678 18,239,065 Diluted effect of purchase options and warrants - - - - Diluted effect of restricted shares - - - - Weighted average shares used in diluted computation 25,214,678 19,375,773 25,214,678 18,239,065 Income per share – Basic: Net income before noncontrolling interest $ (0.05 ) $ 0.01 $ (0.10 ) $ 0.01 Add: Net loss attributable to noncontrolling interest $ - $ - $ - $ - Net income attributable to controlling interest $ (0.05 ) $ 0.01 $ (0.10 ) $ 0.01 Loss per share – Diluted: Net income before noncontrolling interest $ (0.05 ) $ 0.01 $ (0.10 ) $ 0.01 Add: Net income attributable to noncontrolling interest $ - $ - $ - $ - Net income attributable to controlling interest $ (0.05 ) $ 0.01 $ (0.10 ) $ 0.01

Segments (Tables)

Segments (Tables)	6 Months Ended
	Sep. 30, 2017
Segments [Abstract]
Summarized information of segment	Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 15,047,615 $ 3,065,016 5,378,412 - 23,491,043 Cost of goods 10,804,453 2,665,299 4,463,694 - 17,933,446 Gross profit $ 4,243,162 $ 399,717 914,718 - 5,557,597 Selling expenses 2,582,089 459,785 1,308,898 - 4,350,772 General and administrative expenses 2,742,437 107,616 5,361 141 2,855,555 (Loss) income from operations $ (1,081,364 ) $ (167,684 ) (399,541 ) (141 ) (1,648,730 ) Depreciation and amortization $ (416,231 ) $ - 121,767 (119,461 ) (413,925 ) Total capital expenditures $ 149,568 $ - 45,451 - 195,019 * Includes accounts receivable allowance reversal of $654,606 and additional advance to suppliers allowance of $864,554. Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 12,806,987 $ 3,783,725 $ 3,570,123 $ - $ 20,160,835 Cost of goods 9,037,377 3,386,588 3,383,863 - 15,807,828 Gross profit $ 3,769,610 $ 397,137 $ 186,260 $ - $ 4,353,007 Selling expenses 2,192,969 450,866 379,487 - 3,023,322 General and administrative expenses 1,652,375 - (276,910 )* 7,185 1,382,650 (Loss) income from operations $ (75,734 ) $ (53,729 ) $ 83,683 $ (7,185 ) $ (52,965 ) Depreciation and amortization $ 466,051 $ - $ 6,644 $ - $ 472,695 Total capital expenditures $ 40,084 $ - $ - $ - $ 40,084 * Includes accounts receivable and advance to suppliers allowance reversal of $318,789. Retail Online Drug Herb Total Revenue $ 28,067,985 $ 6,200,705 10,892,721 45,161,411 Cost of goods 20,540,661 5,509,797 9,375,695 35,426,153 Gross profit $ 7,527,324 $ 690,908 1,517,026 9,735,258 Selling expenses 5,001,645 975,172 2,290,814 8,267,631 General and administrative expenses 4,012,213 177,905 380,833 10,047 4,580,998 (Loss) income from operations $ (1,486,534 ) $ (462,169 ) (1,154,621 ) (10,047 ) (3,113,371 ) Depreciation and amortization $ (329,242 ) $ - 204,374 (124,868 ) Total capital expenditures $ 206,142 $ - 6,216 212,358 * Includes accounts receivable and advance to suppliers allowance reversal of $280,645. Retail Online Drug Herb Total Revenue $ 25,515,229 $ 8,854,804 $ 6,726,717 $ - $ 41,096,750 Cost of goods 18,124,144 7,800,678 6,337,117 - 32,261,939 Gross profit $ 7,391,085 $ 1,054,126 $ 389,600 $ - $ 8,834,811 Selling expenses 4,401,929 912,912 391,202 - 5,706,043 General and administrative expenses 3,180,948 - 108,476 11,708 3,301,132 (Loss) income from operations $ (191,792 ) $ 141,214 $ (110,078 ) $ (11,708 ) $ (172,364 ) Depreciation and amortization $ 412,859 $ - $ 53,711 $ - $ 466,570 Total capital expenditures $ 49,298 $ - $ - $ - $ 49,298 * Includes accounts receivable and advance to suppliers allowance reversal of $280,645.
Schedule of net revenue from external customers by main products	Three months ended Six months ended 2017 2016 2017 2016 Prescription drugs $ 4,891,435 $ 4,097,127 $ 9,486,789 $ 8,368,229 Over-the-counter drugs 6,780,715 5,188,201 12,424,677 10,063,556 Nutritional supplements 1,638,031 965,346 2,675,363 2,142,086 Traditional Chinese medicine 938,688 1,120,808 1,951,199 2,049,831 Sundry products 362,443 223,799 624,479 478,357 Medical devices 436,303 1,176,034 905,478 2,377,497 Total $ 15,047,615 $ 12,771,315 $ 28,067,985 $ 25,479,556 Three months ended Six months ended 2017 2016 2017 2016 Prescription drugs $ - $ - $ - $ - Over-the-counter drugs 1,385,899 1,309,143 2,503,291 2,946,434 Nutritional supplements 334,806 536,456 850,882 1,444,479 Traditional Chinese medicine 10,182 - 10,182 - Sundry products 422,388 405,341 841,421 1,071,504 Medical devices 911,741 1,532,784 1,994,929 3,392,386 Total $ 3,065,016 $ 3,783,724 $ 6,200,705 $ 8,854,803 Three months ended Six months ended 2017 2016 2017 2016 Prescription drugs $ 3,077,232 $ 1,948,879 $ 6,474,633 $ 3,846,484 Over-the-counter drugs 2,248,503 1,621,129 4,349,153 2,840,030 Nutritional supplements 12,279 31,170 28,537 70,493 Traditional Chinese medicine 604 4,453 604 4,453 Sundry products - - - - Medical devices 39,794 165 39,794 931 Total $ 5,378,412 $ 3,605,796 $ 10,892,721 $ 6,762,391

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Sep. 30, 2017
Commitments and Contingencies [Abstract]
Schedule of Company's commitments for minimum rental payments	Periods ending September 30, Retail Online Drug Herb Total 2018 $ 3,875,101 $ 36,366 $ 72,732 $ - $ 3,984,199 2019 3,462,529 36,366 72,732 - 3,571,627 2020 2,704,078 36,366 72,732 - 2,813,176 2021 2,156,248 12,122 24,244 - 2,192,614 2022 1,653,163 - - - 1,653,163 Thereafter 2,556,744 - - - 2,556,744

Description of Business and O47

Description of Business and Organization (Details)	6 Months Ended
	Sep. 30, 2017
Hangzhou Jiuben Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	Apr. 27, 2017
Hangzhou Jiuli Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	May 22, 2017
Hangzhou Jiuxiang Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	May 26, 2017
Hangzhou Jiuheng Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	Jun. 6, 2017
Hangzhou Jiujiu Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	Jun. 8, 2017
Hangzhou Jiuyi Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	Jun. 8, 2017
Hangzhou Jiuyuan Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	Jul. 13, 2017
Hangzhou Jiumu Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	Jul. 21, 2017
Hangzhou Jiurui Pharmacy Co Ltd [Member]
Variable Interest Entity [Line Items]
Date of established	Aug. 4, 2017

Description of Business and O48

Description of Business and Organization (Details 1)	6 Months Ended
	Sep. 30, 2017
Schedule of consolidated financial statements activities
Entity ownership percentage	100.00%
Renovation [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Incorporated in Hong Kong SAR on September 2, 2008
Entity ownership percentage	100.00%
Jiuxin Management [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC on October 14, 2008 Deemed a wholly foreign owned enterprise(''WFOE'') under PRC law Registered capital of $14.5 million fully paid.
Entity ownership percentage	100.00%
Shouantang Technology [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 millionRegistered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid Deemed a WFOE under PRC law Invests and finances the working capital of Quannuo Technology.
Entity ownership percentage	100.00%
Qianhong Agriculture [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC on August 10, 2010 by Jiuxin Management Registered capital of RMB 10 million fully paid Carries out herb farming business
Entity ownership percentage	100.00%
Jiuzhou Pharmacy [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC on September 9, 2003 Registered capital of RMB 5 million fully paid Operates the “Jiuzhou Grand Pharmacy” stores in Hangzhou	[1]
Entity ownership description	VIE by contractual arrangements	[2]
Jiuzhou Clinic [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC as a general partnership on October 10, 2003 Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores	[1]
Entity ownership description	VIE by contractual arrangements	[2]
Jiuzhou Service [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC on November 2, 2005 Registered capital of RMB 500,000 fully paid Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores	[1]
Entity ownership description	VIE by contractual arrangements	[2]
Jiuxin Medicine [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in PRC on December 31, 2003 Acquired by Jiuzhou Pharmacy in August 2011 Registered capital of RMB 10 million fully paid Carries out pharmaceutical distribution services
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiutong Medical [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC on December 20, 2011 by Renovation Registered capital of $2.6 million fully paid Currently has no operation
Entity ownership percentage	100.00%
Shouantang Bio [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC in October, 2014 by Shouantang Technology 100% held by Shouantang Technology Registered capital of RMB 1,000,000 fully paid Sells nutritional supplements under its own brand name
Entity ownership percentage	100.00%
Jiuyi Technology [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC on September 10, 2015 100% held by Renovation Registered capital of USD 5,000,000 (USD 2,500,000 paid) Technical support to online pharmacy
Entity ownership percentage	100.00%
Kahamadi Bio [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC in May 2016 49% held by Shouantang Bio Registered capital of RMB 10 million Develop brand name for nutritional supplements
Entity ownership percentage	49.00%
Lin' An Jiuzhou [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC in March 31, 2017 100% held by Jiuxin Management Registered capital of RMB 5 million (RMB 550,000 paid) Explore retail pharmacy market in Lin'An City
Entity ownership percentage	100.00%
Jiuben Pharmacy [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC in April 27, 2017 100% held by Jiuzhou Pharmacy Registered capital of RMB 100,000 Operates a retail pharmacy drugstore in Hangzhou City
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiumu Pharmacy [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC in July 21, 2017 100% held by Jiuzhou Pharmacy Registered capital of RMB 100,000 Operates a retail pharmacy drugstore in Hangzhou City
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiuheng Pharmacy [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC in June 6, 2017 100% held by Jiuzhou Pharmacy Registered capital of RMB 100,000 Operates a retail pharmacy drugstore in Hangzhou City
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiujiu Pharmacy [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC in June 8, 2017 100% held by Jiuzhou Pharmacy Registered capital of RMB 100,000 Operates a retail pharmacy drugstore in Hangzhou City
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiuli Pharmacy [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC in May 22 ,2017 100% held by Jiuzhou Pharmacy Registered capital of RMB 100,000 Operates a retail pharmacy drugstore in Hangzhou City
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiurui Pharmacy [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC in August 4, 2017 100% held by Jiuzhou Pharmacy Registered capital of RMB 100,000 Operates a retail pharmacy drugstore in Hangzhou City
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiuxiang Pharmacy [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC in May 26, 2017 100% held by Jiuzhou Pharmacy Registered capital of RMB 100,000 Operates a retail pharmacy drugstore in Hangzhou City
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiuyi Pharmacy [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC in June 8, 2017 100% held by Jiuzhou Pharmacy Registered capital of RMB 100,000 Operates a retail pharmacy drugstore in Hangzhou City
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiuyuan Pharmacy [Member]
Schedule of consolidated financial statements activities
Ownership background, description	Established in the PRC in July 13, 2017 100% held by Jiuzhou Pharmacy Registered capital of RMB 100,000 Registered capital of RMB 100,000
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary ofJiuzhou Pharmacy	[2]
[1]	Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service have been under the common control of Mr. Lei Liu, Mr. Chong'an Jin and Ms. Li Qi, the three shareholders of Renovation (the "Owners") since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting rights agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company's respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy.
[2]	To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity ("VIE") under the accounting standards of the Financial Accounting Standards Board ("FASB"). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiary under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company.

Description of Business and O49

Description of Business and Organization (Details Textual)	1 Months Ended	6 Months Ended
	Sep. 17, 2009shares	Sep. 30, 2017USD ($)	Sep. 30, 2017CNY (¥)	May 31, 2016CNY (¥)	Nov. 30, 2015USD ($)	Nov. 30, 2015CNY (¥)	Dec. 18, 2013
Description of Business and Organization (Textual)
Entity Incorporation, Date of Incorporation		Dec. 19, 2006
Renovation [Member]
Description of Business and Organization (Textual)
Percentage of capital stock in exchange transaction	100.00%
Issuance of equity consideration, shares | shares	7,900,000
Jiuxin Management [Member]
Description of Business and Organization (Textual)
Registered capital paid | $		$ 14,500,000
Shouantang Technology [Member]
Description of Business and Organization (Textual)
Registered capital paid | $		20,000,000
Registered capital requirement reduced | $		11,000,000
Qianhong Agriculture [Member]
Description of Business and Organization (Textual)
Registered capital paid			¥ 10,000,000
Jiuzhou Pharmacy [Member]
Description of Business and Organization (Textual)
Registered capital paid			5,000,000
Jiuzhou Service [Member]
Description of Business and Organization (Textual)
Registered capital paid			500,000
Percentage of ownership							51.00%
Jiuxin Medicine [Member]
Description of Business and Organization (Textual)
Registered capital paid			¥ 10,000,000
Jiutong Medical [Member]
Description of Business and Organization (Textual)
Registered capital paid | $		$ 2,600,000
Shouantang Bio [Member]
Description of Business and Organization (Textual)
Percentage of capital stock in exchange transaction		100.00%	100.00%
Registered capital paid			¥ 1,000,000
Jiuyi Technology [Member]
Description of Business and Organization (Textual)
Percentage of capital stock in exchange transaction		100.00%	100.00%
Registered capital paid | $		$ 5,000,000
Registered capital requirement reduced | $		$ 2,500,000
Quannuo Technology [Member]
Description of Business and Organization (Textual)
Issuance of equity consideration					$ 17,121	¥ 107,074
Kahamadi Bio [Member]
Description of Business and Organization (Textual)
Registered capital paid				¥ 10,000,000
Percentage of ownership				49.00%
Lin' An Jiuzhou [Member]
Description of Business and Organization (Textual)
Registered capital paid			¥ 5,000,000
Percentage of ownership		100.00%	100.00%
Registered capital requirement reduced			¥ 550,000
Jiuben Pharmacy [Member]
Description of Business and Organization (Textual)
Registered capital paid			¥ 100,000
Percentage of ownership		100.00%	100.00%
Jiumu Pharmacy [Member]
Description of Business and Organization (Textual)
Percentage of capital stock in exchange transaction		100.00%	100.00%
Registered capital paid			¥ 100,000
Jiuheng Pharmacy [Member]
Description of Business and Organization (Textual)
Percentage of capital stock in exchange transaction		100.00%	100.00%
Registered capital paid			¥ 100,000
Jiujiu Pharmacy [Member]
Description of Business and Organization (Textual)
Percentage of capital stock in exchange transaction		100.00%	100.00%
Registered capital paid			¥ 100,000
Jiuli Pharmacy [Member]
Description of Business and Organization (Textual)
Percentage of capital stock in exchange transaction		100.00%	100.00%
Registered capital paid			¥ 100,000
Jiurui Pharmacy [Member]
Description of Business and Organization (Textual)
Percentage of capital stock in exchange transaction		100.00%	100.00%
Registered capital paid			¥ 100,000
Jiuxiang Pharmacy [Member]
Description of Business and Organization (Textual)
Percentage of capital stock in exchange transaction		100.00%	100.00%
Registered capital paid			¥ 100,000
Jiuyi Pharmacy [Member]
Description of Business and Organization (Textual)
Percentage of capital stock in exchange transaction		100.00%	100.00%
Registered capital paid			¥ 100,000
Jiuyuan Pharmacy [Member]
Description of Business and Organization (Textual)
Percentage of capital stock in exchange transaction		100.00%	100.00%
Registered capital paid			¥ 100,000

Summary of Significant Accoun50

Summary of Significant Accounting Policies (Details)	Sep. 30, 2017USD ($)
Summary of fair values of derivative instruments
Cash and cash equivalents	$ 16,837,873
Notes payable	12,872,045
Warrants liability	297,466
Total	30,007,384
Active Market for Identical Assets (Level 1) [Member]
Summary of fair values of derivative instruments
Cash and cash equivalents	16,837,873
Notes payable
Warrants liability
Total	16,837,873
Observable Inputs (Level 2) [Member]
Summary of fair values of derivative instruments
Cash and cash equivalents
Notes payable	12,872,045
Warrants liability	297,466
Total	13,169,511
Unobservable Inputs (Level 3) [Member]
Summary of fair values of derivative instruments
Cash and cash equivalents
Notes payable
Warrants liability
Total

Summary of Significant Accoun51

Summary of Significant Accounting Policies (Details 1)	6 Months Ended
	Sep. 30, 2017
Leasehold improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	10 years
Leasehold improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	3 years
Motor vehicles [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	5 years
Motor vehicles [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	3 years
Office equipment & furniture [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	5 years
Office equipment & furniture [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	3 years
Buildings [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	35 years

Summary of Significant Accoun52

Summary of Significant Accounting Policies (Details 2)	6 Months Ended
	Sep. 30, 2017
Land use rights [Member]
Schedule of estimated useful lives of intangible assets
Estimated useful life of intangible assets	50 years
Software [Member]
Schedule of estimated useful lives of intangible assets
Estimated useful life of intangible assets	3 years

Summary of Significant Accoun53

Summary of Significant Accounting Policies (Details Textual)	3 Months Ended		6 Months Ended
	Sep. 30, 2017USD ($)Suppliers	Sep. 30, 2016USD ($)Suppliers	Sep. 30, 2017USD ($)Suppliers	Sep. 30, 2016USD ($)Suppliers	Sep. 30, 2017CNY (¥)	Mar. 31, 2017USD ($)	Mar. 31, 2015USD ($)	Mar. 31, 2015CNY (¥)
Summary of Significant Accounting Policies (Textual)
Voting ownership interest			50.00%
Ownership percentage			100.00%
Value added tax, percentage			17.00%
Income tax, description			The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. The Company performed a self-assessment and the Company's liability for income taxes includes liability for unrecognized tax benefits, interest and penalties which relate to tax years still subject to review by taxing authorities. Audit periods remain open for review until the statute of limitations has passed, which in the PRC is usually 5 years.
Advertising and promotion costs	$ 180,639	$ 113,638	$ 320,734	$ 182,487
Term of agreement for operating leases			30 years
Foreign currency translation, description			The balance sheet amounts, with the exception of equity, at September 30, 2017 and at March 31, 2017 were translated at 1 RMB to 0.1503 USD and at 1 RMB to 0.1451 USD, respectively. The average translation rates applied to income and cash flow statement amounts for the six months ended September 30, 2017 and 2016 were at at 1 RMB to 0.1478 USD and 1 RMB to 0.1515 USD, respectively.
Insurance covered by own bank							$ 77,150	¥ 500,000
Deposits	26,709,868		$ 26,709,868			$ 27,357,785
Deposits not covered by insurance	$ 75,150		75,150		¥ 500,000
Farmland assets [Member]
Summary of Significant Accounting Policies (Textual)
Impairment of assets			$ 0
Total purchases [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk, percentage	61.30%	30.70%	39.60%	38.60%
Number of vendors | Suppliers	3	1	2	2
Total advances to suppliers [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk, percentage	16.80%	9.90%	16.80%	9.90%
Number of vendors | Suppliers	1	1	1	1
Total sales [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk, percentage			10.00%	10.00%
Total sales or accounts receivable [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk, percentage	10.00%	10.00%	10.00%	10.00%
Retail drugstore leases [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Textual)
Term of agreement for operating leases			3 years
Retail drugstore leases [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Textual)
Term of agreement for operating leases			10 years
Wholesale warehouse lease [Member]
Summary of Significant Accounting Policies (Textual)
Term of agreement for operating leases			10 years

Financial Assets Available fo54

Financial Assets Available for Sale (Details)	Sep. 30, 2017USD ($)	Sep. 30, 2017CNY (¥)	Mar. 31, 2017USD ($)	Mar. 31, 2017CNY (¥)
Financial Assets Available for Sale (Textual)
Financial assets available for sale	$ 165,282	¥ 1,100,000	$ 87,068	¥ 600,000
Investment agreement fund	$ 300,600	¥ 2,000,000

Trade Accounts Receivable (Deta

Trade Accounts Receivable (Details) - USD ($)	Sep. 30, 2017	Mar. 31, 2017
Trade Accounts Receivable/Other Receivable [Abstract]
Accounts receivable	$ 12,270,651	$ 9,977,101
Less: allowance for doubtful accounts	(2,070,109)	(1,415,505)
Trade accounts receivable, net	$ 10,200,542	$ 8,561,596

Trade Accounts Receivable (De56

Trade Accounts Receivable (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Trade Accounts Receivable (Textual)
Accounts receivable written off	$ 98,590	$ 30,790	$ 124,983	$ 63,382

Other Receivable (Details)

Other Receivable (Details) - USD ($)		Sep. 30, 2017	Mar. 31, 2017
Trade Accounts Receivable/Other Receivable [Abstract]
Deposit	[1]	$ 1,216,800	$ 855,755
Advance to employees		584,996	652,436
Accrued supplier rebate	[2]	190,554	321,993
Interest receivable	[3]	240,410
Others		418,825	465,593
Less: allowance for doubtful accounts		(27,526)	(26,584)
Other receivable, net		$ 2,624,059	$ 2,269,193
[1]	It refers to various advances deposits made to service providers and commercial platforms such as Alibaba's Tmall, in order to carry business via these service providers and platforms.
[2]	It refers to supplier rebate receivables, which are computed based on our sales volume of the suppliers' products.
[3]	It refers to accrued interest receivable from several three-year bank deposits, which are used as a pledge for bank-guranteed notes payable (see Note 14).

Other Current Assets (Details)

Other Current Assets (Details) - USD ($)		Sep. 30, 2017	Mar. 31, 2017
Other Current Assets [Abstract]
Prepaid rental expenses	[1]	$ 1,395,985	$ 1,171,472
Prepaid and other current assets		408,669	394,683
Total		$ 1,804,654	$ 1,566,155
[1]	Represents store and office rental expenses that were usually prepaid and amortized over the prepayment period. The increase reflects additional prepaid rental for new stores.

Property and Equipment (Details

Property and Equipment (Details) - USD ($)		Sep. 30, 2017	Mar. 31, 2017
Property, Plant and Equipment [Line Items]
Total		$ 21,239,883	$ 20,999,783
Less: Accumulated depreciation		(14,861,284)	(14,489,479)
Impairment	[1]	(2,365,317)	(2,247,147)
Construction-in-progress	[2]	520,108	0
Property and equipment, net		4,533,390	4,263,157
Building [Member]
Property, Plant and Equipment [Line Items]
Total		1,611,055	1,555,923
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Total		12,229,600	11,783,611
Farmland development cost [Member]
Property, Plant and Equipment [Line Items]
Total		1,796,971	1,735,475
Office equipment and furniture [Member]
Property, Plant and Equipment [Line Items]
Total		5,126,811	5,339,005
Motor vehicles [Member]
Property, Plant and Equipment [Line Items]
Total		$ 475,446	$ 585,769
[1]	The variance of impairment from March 31, 2017 to September 30, 2017 is solely caused by exchange rate variance.
[2]	Includes clinic renovation expense of $70,798 and SAP (a popular ERP software) implementation fee of $449,309. The clinic renovation has been completed at the end of October 2017. SAP system is expected to be implemented by the end of 2017.

Property and Equipment (Detai60

Property and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2017
Property and Equipment (Textual)
Depreciation expense for property and equipment	$ 171,051	$ 213,969	$ 576,154	$ 452,979
Impairment of land and road improvement					$ 106,257
ERP software implementation fee			449,309
Clinic renovation expense	$ 70,798		$ 70,798

Advances to Suppliers (Details)

Advances to Suppliers (Details) - USD ($)	Sep. 30, 2017	Mar. 31, 2017
Advances to Suppliers [Abstract]
Advance to suppliers	$ 6,280,908	$ 7,006,396
Less: allowance for doubtful accounts	(2,366,809)	(1,502,255)
Advance to suppliers, net	$ 3,914,099	$ 5,504,141

Inventory (Details)

Inventory (Details) - USD ($)	Sep. 30, 2017	Mar. 31, 2017
Inventory (Textual)
Finished goods	$ 11,077,027	$ 9,923,101

Farmland Assets (Details)

Farmland Assets (Details) - USD ($)		Sep. 30, 2017	Mar. 31, 2017
Farmland Assets [Abstract]
Farmland assets		$ 2,273,593	$ 2,195,787
Less: Impairment	[1]	(1,529,337)	(1,477,000)
Farmland assets, net		$ 744,256	$ 718,787
[1]	The estimated fair value is estimated to be lower than its investment value as of September 30, 2017 and March 31, 2017.

Long Term Deposits, Landlords (

Long Term Deposits, Landlords (Details) - USD ($)	Sep. 30, 2017	Mar. 31, 2017
Long Term Deposits, Landlords (Textual)
Long term deposits	$ 3,202,793	$ 2,294,848

Other Noncurrent Assets (Detail

Other Noncurrent Assets (Details) - USD ($)		Sep. 30, 2017	Mar. 31, 2017
Other Noncurrent Assets [Abstract]
Forest land use rights	[1]	$ 1,192,217	$ 1,177,005
Long-term prepaid store rent (over one year)	[2]	135,230
Total		$ 1,327,447	$ 1,177,005
[1]	The prepayment for lease of forest land use rights is a payment made to a local government in connection with entering into an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060.
[2]	In order to secure better terms in a lease agreement, the Company agreed to pay two-year rent at the beginning of the lease.

Other Noncurrent Assets (Deta66

Other Noncurrent Assets (Details 1)	Sep. 30, 2017USD ($)
For the year ending september 30,
2,018	$ 28,233
2,019	28,233
2,020	28,233
2,021	28,233
2,022	28,233
Thereafter	$ 1,057,869

Other Noncurrent Assets (Deta67

Other Noncurrent Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Other Noncurrent Assets (Textual)
Amortization of prepayment for lease of land use right	$ 7,042	$ 15,484	$ 13,888	$ 31,298
Description of lease prepayment life			Extends the life of the lease to January 31, 2060.

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)		Sep. 30, 2017	Mar. 31, 2017
Acquired Finite-Lived Intangible Assets [Line Items]
Total intangible assets		$ 3,212,706	$ 2,809,632
Less: accumulated amortization		(115,160)	(97,021)
Intangible assets, net		3,097,546	2,712,611
License [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Total intangible assets	[1]	1,747,477	1,394,546
Land use rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Total intangible assets	[2]	$ 1,465,229	$ 1,415,086
[1]	This represents the fair value of the licenses of insurance applicable drugstores acquired from Sanhao Pharmacy, a drugstore chain Jiuzhou Pharmacy acquired in 2014. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. The owners of these acquried drugstores agreed to cease their stores' business and liquidate all of the stores' accounts before Jiuzhou Pharmacy acquired their stores. As a result, Jiuzhou Pharmacy has not obtained any assets or liabilities from the stores, but was able to transfer the Certificate to our new store opened at the same time.
[2]	In July 2013, the Company purchased the land use rights of a plot of farmland in Lin'an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as our farming business in Lin'an has not grown, the Company does not expect completion of the plant in the near future.

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Intangible Assets (Textual)
Amortization expense of intangibles	$ 7,334	$ 6,101	$ 14,464	$ 13,591

Notes Payable (Details)

Notes Payable (Details) - USD ($)		6 Months Ended
		Sep. 30, 2017	Mar. 31, 2017
Short-term Debt [Line Items]
Notes payable		$ 12,872,045	$ 12,691,575
Jiuzhou Pharmacy [Member] | HUB [Member] | 10/09/16 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Apr. 9, 2017
Notes payable	[1]		1,755,879
Jiuzhou Pharmacy [Member] | HUB [Member] | 10/09/16 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Apr. 9, 2017
Notes payable	[1]		341,676
Jiuzhou Pharmacy [Member] | HUB [Member] | 11/08/16 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	May 8, 2017
Notes payable	[1]		1,637,419
Jiuzhou Pharmacy [Member] | HUB [Member] | 11/11/16 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	May 11, 2017
Notes payable	[1]		314,897
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/05/16 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Jun. 5, 2017
Notes payable	[1]		1,508,042
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/29/16 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Jun. 29, 2017
Notes payable	[1]		1,205,419
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/29/16 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Jun. 29, 2017
Notes payable	[1]		1,030,309
Jiuzhou Pharmacy [Member] | HUB [Member] | 02/06/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Aug. 6, 2017
Notes payable	[1]		2,253,804
Jiuzhou Pharmacy [Member] | HUB [Member] | 03/07/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Sep. 7, 2017
Notes payable	[1]		117,542
Jiuzhou Pharmacy [Member] | HUB [Member] | 03/07/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Sep. 7, 2017
Notes payable	[1]		267,651
Jiuzhou Pharmacy [Member] | HUB [Member] | 03/07/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Sep. 7, 2017
Notes payable	[1]		1,678,481
Jiuzhou Pharmacy [Member] | HUB [Member] | 04/05/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Oct. 5, 2017
Notes payable	[1]	$ 1,345,036
Jiuzhou Pharmacy [Member] | HUB [Member] | 05/04/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Nov. 4, 2017
Notes payable	[1]	$ 1,806,808
Jiuzhou Pharmacy [Member] | HUB [Member] | 06/05/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Dec. 5, 2017
Notes payable	[1]	$ 1,561,478
Jiuzhou Pharmacy [Member] | HUB [Member] | 06/05/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Dec. 5, 2017
Notes payable	[1]	$ 354,534
Jiuzhou Pharmacy [Member] | HUB [Member] | 06/29/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Dec. 29, 2017
Notes payable	[1]	$ 1,074,330
Jiuzhou Pharmacy [Member] | HUB [Member] | 06/29/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Dec. 29, 2017
Notes payable	[1]	$ 826,408
Jiuzhou Pharmacy [Member] | HUB [Member] | 06/29/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Dec. 29, 2017
Notes payable	[1]	$ 1,984,650
Jiuzhou Pharmacy [Member] | HUB [Member] | 08/09/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Feb. 9, 2018
Notes payable	[1]	$ 1,357,600
Jiuzhou Pharmacy [Member] | HUB [Member] | 09/05/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Dec. 5, 2017
Notes payable	[1]	$ 267,756
Jiuzhou Pharmacy [Member] | HUB [Member] | 09/05/17 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Mar. 5, 2018
Notes payable	[1]	$ 2,293,445
Jiuzhou Pharmacy [Member] | ZTCB [Member] | 12/27/16 [Member]
Short-term Debt [Line Items]
Maturity date	[2]	Jun. 27, 2017
Notes payable	[2]		$ 580,456
[1]	As of March 31, 2017, the Company had $12,111,119 (RMB 81,459,343.5) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $1,328,098 (RMB 9,152,104.2) with HUB as collateral against these bank notes. As of September 30, 2017, the Company had $12,872,045 (RMB 85667428.6) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $1,432,935 (RMB 9,536,623) with HUB as collateral against these bank notes. Additionally, a total of $8,785,866 deposit (RMB 58,472,647.3), which matures in three years, was deposited into HUB as a collateral for current and future notes payable from HUB.
[2]	As of March 31, 2017, the Company had $580,456 (RMB 4,000,000) of notes payable from ZTCB, with restricted cash in the amount of $290,228 (RMB 2,000,000) held at the bank. As of September 30, 2017, the Company had no notes payable from ZTCB.

Notes Payable (Details Textual)

Notes Payable (Details Textual)	6 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2017CNY (¥)	Mar. 31, 2017USD ($)	Mar. 31, 2017CNY (¥)
Notes Payable (Textual)
Notes payable	$ 12,870,000
Restricted cash	1,430,000
Line of credit total	18,170,000
Bank credit line facilities available for borrowing	5,300,000
HUB [Member]
Notes Payable (Textual)
Aggregate line of credit amount	16,740,000
BOH [Member]
Notes Payable (Textual)
Aggregate line of credit amount	16,740,000
ICBC [Member]
Notes Payable (Textual)
Aggregate line of credit amount	16,740,000
ZTCB [Member]
Notes Payable (Textual)
Aggregate line of credit amount	16,740,000
Notes Payable [Member] | HUB [Member]
Notes Payable (Textual)
Notes payable	12,872,045	¥ 85,667,428.6	$ 12,111,119	¥ 81,459,343.5
Restricted cash	$ 1,432,935	9,536,623	1,328,098	9,152,104.2
Term of deposit	3 years
Notes Payable [Member] | HUB One [Member]
Notes Payable (Textual)
Notes payable	$ 8,785,866	¥ 58,472,647.3
Notes Payable [Member] | ZTCB [Member]
Notes Payable (Textual)
Notes payable			580,456	4,000,000
Restricted cash			$ 290,228	¥ 2,000,000

Taxes (Details)

Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Taxes [Abstract]
Income tax	$ 18,047	$ 17,484	$ 38,585	$ 49,518

Taxes (Details 1)

Taxes (Details 1)	6 Months Ended
	Sep. 30, 2017
Jo-Jo Drugstores [Member]
Income Taxes [Line Items]
Income Tax Jurisdiction	United States
Renovation [Member]
Income Taxes [Line Items]
Income Tax Jurisdiction	Hong Kong, PRC
All other entities [Member]
Income Taxes [Line Items]
Income Tax Jurisdiction	Mainland, PRC

Taxes (Details 2)

Taxes (Details 2)		3 Months Ended		6 Months Ended
		Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Taxes [Abstract]
U.S. Statutory rates		34.00%	34.00%	34.00%	34.00%
Foreign income not recognized in the U.S.		(34.00%)	(34.00%)	(34.00%)	(34.00%)
China income taxes		25.00%	25.00%	25.00%	25.00%
Change in valuation allowance	[1]	(18.40%)	(25.00%)	(22.90%)	(25.00%)
Non-deductible expenses-permanent difference	[2]	(8.20%)	15.20%	(3.60%)	16.70%
Effective tax rate		(1.60%)	15.20%	(1.50%)	16.70%
[1]	Represents non-taxable expense reversal due to overall decrease in allowance for accounts receivables and advance to suppliers.
[2]	The (1.6)% and 15.2% rate adjustments for the three months ended September 30, 2017 and 2016, and the (1.5)% and 16.7% rate adjustments for the six months ended September 30, 2017 and 2016 represent expenses primarily including stock option expenses, legal, accounting and other expenses incurred by the Company that were not deductible for PRC income tax.

Taxes (Details 3)

Taxes (Details 3) - USD ($)	Sep. 30, 2017	Mar. 31, 2017
Taxes [Abstract]
VAT	$ 515,358	$ 615,067
Income tax	18,494	19,416
Others	36,779	47,456
Total taxes payable	$ 570,631	$ 681,939

Taxes (Details Textual)

Taxes (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Taxes (Textual)
Estimated net operating loss carry forwards for U.S. income tax purposes	$ 1,503,000		$ 1,503,000
Expiration date			Mar. 31, 2032
Valuation allowance, percentage			100.00%
Effective tax rate	(1.60%)	15.20%	(1.50%)	16.70%

Postretirement Benefits (Detail

Postretirement Benefits (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Postretirement Benefits (Textual)
Employment benefits and pension contribution	$ 276,490	$ 222,732	$ 559,734	$ 470,632

Related Party Transactions an78

Related Party Transactions and Arrangements (Details) - USD ($)		Sep. 30, 2017	Mar. 31, 2017
Due to a director and CEO [Member]
Related Party Transaction [Line Items]
Amounts payable to related parties, Total	[1]	$ 755,734	$ 927,052
[1]	Due to foreign exchange restrictions, the Company's director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States.

Related Party Transactions an79

Related Party Transactions and Arrangements (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2017
Related Party Transactions and Arrangements (Textual)
Notes payable, related parties	$ 3,684,220		$ 3,684,220		$ 3,974,193
Mr. Lei Liu [Member]
Related Party Transactions and Arrangements (Textual)
Lease expiration date			Sep. 30, 2018
Rent expenses	$ 4,435	$ 4,499	$ 8,870	$ 9,092

Warrants (Details)

Warrants (Details) - Common Stock Warrants [Member] - $ / shares	6 Months Ended		12 Months Ended
	Sep. 30, 2017	[1]	Mar. 31, 2017
Class of Warrant or Right [Line Items]
Stock price	$ 1.62		$ 1.80
Exercise price	$ 3.10		$ 3.10
Annual dividend yield
Expected term (years)	3 years 3 months 19 days		3 years 9 months 18 days
Risk-free interest rate	1.62%		0.87%
Expected volatility	70.81%		90.73%
[1]	As of September 30, 2017, the warrants had not been exercised.

Warrants (Details Textual)

Warrants (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Jul. 19, 2015	Sep. 30, 2017	Sep. 30, 2017	Mar. 31, 2017
Warrants (Textual)
Fair value estimation method			Binominal pricing model
Fair value of warrant liability				$ 496,217
Purchase of warrants investors			672,000
Recognized gain on fair value of warrant liability investor placement agent		$ 148,427	$ 198,751
Fair value of warrant liability investor placement agent			$ 297,466
Warrants [Member]
Warrants (Textual)
Stock purchase price per share (in dollars per share)	$ 3.10
Maturity date	Jan. 18, 2021
Purchase of warrants investors	600,000
Issuance of warrants to placement agent			72,000
Percentage of stock sold in offering			6.00%

Stockholder's Equity (Details)

Stockholder's Equity (Details)	Jun. 03, 2016$ / sharesshares	Nov. 18, 2014Segment$ / sharesshares	Jan. 23, 2017USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)
Stockholder's Equity (Textual)
Reserve fund percentage						50.00%
Statutory accounts percentage						10.00%
Common Stock [Member]
Stockholder's Equity (Textual)
Company sold common stock to investor | shares			4,840,000
Common stock, par value | $ / shares			$ 0.001
Purchase price | $ / shares			$ 2.20
Proceeds from private placement | $			$ 10,648,000
Stock option [Member]
Stockholder's Equity (Textual)
Number of granted shares | shares		967,000
Share based compensation expense | $				$ 124,033	$ 124,033	$ 248,066	$ 248,066
Number of directors, officers and employees in a group | Segment		46
Exercise price of stock option | $ / shares		$ 2.50
Period for options exercisable from the vesting date		5 years				1 month 16 days
Maturity date		Nov. 17, 2022
Unrecognized compensation costs | $				70,000		$ 70,000
Stock-based compensation to employees in retail drugstores and online pharmacy [Member]
Stockholder's Equity (Textual)
Number of granted shares | shares	1,630,000
Trading value of common stock | $ / shares	$ 1.62
Share based compensation expense | $				$ 221,859	$ 221,859	$ 441,306	$ 286,970
Vesting period of options	3 years

(Loss) Income Per Share(Details

(Loss) Income Per Share(Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
(Loss) Income Per Share [Abstract]
Net income attributable to controlling interest	$ (1,168,709)	$ 97,870	$ (2,588,013)	$ 229,023
Weighted average shares used in basic computation	25,214,678	19,375,773	25,214,678	18,239,065
Diluted effect of purchase options and warrants
Diluted effect of restricted shares
Weighted average shares used in diluted computation	25,214,678	19,375,773	25,214,678	18,239,065
Income per share - Basic:
Net income before noncontrolling interest	$ (0.05)	$ 0.01	$ (0.10)	$ 0.01
Add: Net loss attributable to noncontrolling interest
Net income attributable to controlling interest	(0.05)	0.01	(0.10)	0.01
Loss per share - Diluted:
Net income before noncontrolling interest	(0.05)	0.01	(0.10)	0.01
Add: Net income attributable to noncontrolling interest
Net income attributable to controlling interest	$ (0.05)	$ 0.01	$ (0.10)	$ 0.01

(Loss) Income Per Share (Detail

(Loss) Income Per Share (Details Textual) - Stock options [Member] - shares	3 Months Ended	6 Months Ended
	Sep. 30, 2017	Sep. 30, 2017
(Loss) Income Per Share (Textual)
Antidilutive securities excluded from calculation of diluted earnings per share	967,000	967,000
Investment placement agent [Member]
(Loss) Income Per Share (Textual)
Antidilutive securities excluded from calculation of diluted earnings per share	72,000	72,000
Investor [Member]
(Loss) Income Per Share (Textual)
Antidilutive securities excluded from calculation of diluted earnings per share	600,000	600,000

Segments (Details)

Segments (Details) - USD ($)	3 Months Ended			6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016		Sep. 30, 2017	Sep. 30, 2016
Segment Reporting Information [Line Items]
Revenue	$ 23,491,043	$ 20,160,835		$ 45,161,411	$ 41,096,750
Cost of goods	17,933,446	15,807,828		35,426,153	32,261,939
Gross profit	5,557,597	4,353,007		9,735,258	8,834,811
Selling expenses	4,350,772	3,023,322		8,267,631	5,706,043
General and administrative expenses	2,855,555	1,382,650		4,580,998	3,301,132
(Loss) income from operations	(1,648,730)	(52,965)		(3,113,371)	(172,364)
Depreciation and amortization	(413,925)	472,695		(124,868)	466,570
Total capital expenditures	195,019	40,084		212,358	49,298
Retail drugstores [Member]
Segment Reporting Information [Line Items]
Revenue	15,047,615	12,806,987		28,067,985	25,515,229
Cost of goods	10,804,453	9,037,377		20,540,661	18,124,144
Gross profit	4,243,162	3,769,610		7,527,324	7,391,085
Selling expenses	2,582,089	2,192,969		5,001,645	4,401,929
General and administrative expenses	2,742,437	1,652,375		4,012,213	3,180,948
(Loss) income from operations	(1,081,364)	(75,734)		(1,486,534)	(191,792)
Depreciation and amortization	(416,231)	466,051		(329,242)	412,859
Total capital expenditures	149,568	40,084		206,142	49,298
Online Pharmacy [Member]
Segment Reporting Information [Line Items]
Revenue	3,065,016	3,783,725		6,200,705	8,854,804
Cost of goods	2,665,299	3,386,588		5,509,797	7,800,678
Gross profit	399,717	397,137		690,908	1,054,126
Selling expenses	459,785	450,866		975,172	912,912
General and administrative expenses	107,616			177,905
(Loss) income from operations	(167,684)	(53,729)		(462,169)	141,214
Depreciation and amortization
Total capital expenditures
Drug wholesale [Member]
Segment Reporting Information [Line Items]
Revenue	5,378,412	3,570,123		10,892,721	6,726,717
Cost of goods	4,463,694	3,383,863		9,375,695	6,337,117
Gross profit	914,718	186,260		1,517,026	389,600
Selling expenses	1,308,898	379,487		2,290,814	391,202
General and administrative expenses	5,361	(276,910)	[1]	380,833	108,476
(Loss) income from operations	(399,541)	83,683		(1,154,621)	(110,078)
Depreciation and amortization	121,767	6,644		204,374	53,711
Total capital expenditures	45,451			6,216
Herb farming [Member]
Segment Reporting Information [Line Items]
Revenue
Cost of goods
Gross profit
Selling expenses
General and administrative expenses	141	7,185		10,047	11,708
(Loss) income from operations	(141)	(7,185)		$ (10,047)	(11,708)
Depreciation and amortization	(119,461)
Total capital expenditures
[1]	Includes accounts receivable and advance to suppliers allowance reversal of $318,789.

Segments (Details 1)

Segments (Details 1) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue from External Customer [Line Items]
Net revenue from external customers	$ 23,491,043	$ 20,160,835	$ 45,161,411	$ 41,096,750
Retail drugstores [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	15,047,615	12,771,315	28,067,985	25,479,556
Retail drugstores [Member] | Prescription drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	4,891,435	4,097,127	9,486,789	8,368,229
Retail drugstores [Member] | Over-the-counter drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	6,780,715	5,188,201	12,424,677	10,063,556
Retail drugstores [Member] | Nutritional supplements [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	1,638,031	965,346	2,675,363	2,142,086
Retail drugstores [Member] | Traditional Chinese medicine [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	938,688	1,120,808	1,951,199	2,049,831
Retail drugstores [Member] | Sundry products [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	362,443	223,799	624,479	478,357
Retail drugstores [Member] | Medical devices [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	436,303	1,176,034	905,478	2,377,497
Online Pharmacy [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	3,065,016	3,783,724	6,200,705	8,854,803
Online Pharmacy [Member] | Prescription drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers
Online Pharmacy [Member] | Over-the-counter drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	1,385,899	1,309,143	2,503,291	2,946,434
Online Pharmacy [Member] | Nutritional supplements [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	334,806	536,456	850,882	1,444,479
Online Pharmacy [Member] | Traditional Chinese medicine [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	10,182		10,182
Online Pharmacy [Member] | Sundry products [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	422,388	405,341	841,421	1,071,504
Online Pharmacy [Member] | Medical devices [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	911,741	1,532,784	1,994,929	3,392,386
Drug wholesale [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	5,378,412	3,605,796	10,892,721	6,762,391
Drug wholesale [Member] | Prescription drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	3,077,232	1,948,879	6,474,633	3,846,484
Drug wholesale [Member] | Over-the-counter drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	2,248,503	1,621,129	4,349,153	2,840,030
Drug wholesale [Member] | Nutritional supplements [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	12,279	31,170	28,537	70,493
Drug wholesale [Member] | Traditional Chinese medicine [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	604	4,453	604	4,453
Drug wholesale [Member] | Sundry products [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers
Drug wholesale [Member] | Medical devices [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	$ 39,794	$ 165	$ 39,794	$ 931

Segments (Details Textual)

Segments (Details Textual)	3 Months Ended	6 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2017USD ($)Segment	Sep. 30, 2016USD ($)
Segments (Textual)
Number of operating segments | Segment		4
Operating Segments [Member]
Segments (Textual)
Accounts receivable and advance to supplier allowance reversal	$ 654,606
Accounts receivable allowance reversal	318,789	$ 280,645	$ 280,645
Additional advance to suppliers allowance	$ 864,554

Commitments and Contingencies88

Commitments and Contingencies (Details)	Sep. 30, 2017USD ($)
Commitments and Contingencies [Line Items]
2,018	$ 3,984,199
2,019	3,571,627
2,020	2,813,176
2,021	2,192,614
2,022	1,653,163
Thereafter	2,556,744
Retail drugstores [Member]
Commitments and Contingencies [Line Items]
2,018	3,875,101
2,019	3,462,529
2,020	2,704,078
2,021	2,156,248
2,022	1,653,163
Thereafter	2,556,744
Online Pharmacy [Member]
Commitments and Contingencies [Line Items]
2,018	36,366
2,019	36,366
2,020	36,366
2,021	12,122
2,022
Thereafter
Drug wholesale [Member]
Commitments and Contingencies [Line Items]
2,018	72,732
2,019	72,732
2,020	72,732
2,021	24,244
2,022
Thereafter
Herb farming [Member]
Commitments and Contingencies [Line Items]
2,018
2,019
2,020
2,021
2,022
Thereafter

Commitments and Contingencies89

Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Commitments and Contingencies (Textual)
Total rent expenses	$ 1,076,749	$ 722,190